<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of the management of epidermolysis bullosa</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of the management of epidermolysis bullosa</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of the management of epidermolysis bullosa</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Dedee F Murrell, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer L Hand, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 08, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3062885540"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Epidermolysis bullosa (EB) is a heterogeneous group of hereditary mechanobullous diseases characterized by varying degrees of skin and mucosa fragility caused by mutations that affect skin structural proteins. There are four major types of EB, based upon the ultrastructural level of tissue cleavage in the skin: epidermolysis bullosa simplex (EBS), junctional epidermolysis bullosa (JEB), dystrophic epidermolysis bullosa (DEB), and Kindler epidermolysis bullosa (KEB)  (<a class="graphic graphic_table graphicRef76897" href="/d/graphic/76897.html" rel="external">table 1</a>) [<a href="#rid1">1-3</a>]. Severity is determined by the level of blistering and type of mutation and is highly variable among subtypes of EB  (<a class="graphic graphic_table graphicRef77709 graphicRef67202 graphicRef55262" href="/d/graphic/77709.html" rel="external">table 2A-C</a>).</p><p>There is no targeted therapy for EB, although this is an active area of investigation [<a href="#rid4">4-6</a>]. The management of patients with EB is largely supportive and includes wound care and prevention and treatment of complications.</p><p>This topic will provide an overview of the management of EB. The pathogenesis, clinical characteristics, and diagnosis of EB are discussed separately. (See  <a class="medical medical_review" href="/d/html/15449.html" rel="external">"Epidermolysis bullosa: Epidemiology, pathogenesis, classification, and clinical features"</a> and  <a class="medical medical_review" href="/d/html/15452.html" rel="external">"Diagnosis of epidermolysis bullosa"</a>.)</p><p class="headingAnchor" id="H10204934"><span class="h1">GENERAL PRINCIPLES</span></p><p class="headingAnchor" id="H70257089"><span class="h2">Supportive care</span><span class="headingEndMark"> — </span>There is no specific therapy for most forms of epidermolysis bullosa (EB). Treatment is largely supportive and includes wound care, control of infection, nutritional support, and prevention and treatment of complications.</p><p>The management of patients with EB involves a multidisciplinary team usually composed of a dermatologist, an EB nurse with specialized expertise in wound care, primary care provider, occupational therapist, nutritionist, and social worker. Specialists, including gastroenterology, ophthalmology, nephrology, hematology, endocrinology, cardiology, pain management, psychiatry, genetics, plastic surgery, and specialized dentistry, are consulted as needed. This multidisciplinary approach is emphasized by published consensus recommendations for the management of inherited EB [<a href="#rid7">7,8</a>].</p><p>Care plans for patients with EB should be individualized according to age, severity, symptoms, complications, and patient priorities. We typically see patients with severe forms of EB, such as severe, generalized recessive dystrophic epidermolysis bullosa (RDEB) or junctional epidermolysis bullosa (JEB), at three- to six-month intervals. They often require inpatient multidisciplinary care. Patients with less severe forms of EB, such as localized epidermolysis bullosa simplex (EBS) or mild dominant dystrophic epidermolysis bullosa (DDEB), can be seen once a year in specialized outpatient clinics.</p><p>The burden for caregivers of children with severe forms of EB is enormous [<a href="#rid9">9</a>]. Support groups in the community, such as the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.debra.org%2F&amp;token=ZAuWdG5s4GIvjFnkWRP6rBhDauAum10yKoDutiIm2iU%3D&amp;TOPIC_ID=15453" target="_blank">Dystrophic Epidermolysis Bullosa Research Association</a>, are important for caregivers of children with this chronic, debilitating disease.</p><p class="headingAnchor" id="H70257120"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span>Laboratory and imaging monitoring is an important aspect of the management of patients with EB. Patients with EB require regular monitoring for complications and sequelae. The laboratory and imaging tests and the frequency of these tests vary depending upon the type of EB and the presence of complications  (<a class="graphic graphic_table graphicRef87123" href="/d/graphic/87123.html" rel="external">table 3</a>) [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H567085620"><span class="h1">MANAGEMENT DURING COVID-19 PANDEMIC</span><span class="headingEndMark"> — </span>Recommendations for multidisciplinary care of epidermolysis bullosa (EB) during the coronavirus disease 2019 (COVID-19) pandemic were drafted by an international panel of experts [<a href="#rid11">11</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with a low risk of internal disease and cutaneous squamous cell carcinoma (cSCC; eg, patients with epidermolysis bullosa simplex [EBS], dominant dystrophic epidermolysis bullosa [DDEB], localized junctional epidermolysis bullosa [JEB]) may be followed by teledermatology visits and have laboratory tests as needed at local laboratories.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with a high risk of cSCC and cutaneous lesions suspicious for cSCC (eg, persistent, growing, or painful lesions) need to be seen in person, and the suspicious lesion should be biopsied.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Surgical masks, gowns, visors/goggles, and gloves should be worn by all nursing and medical staff when consulting with patients with EB, for both patient and staff protection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Testing for COVID-19 using nasopharyngeal swabs should be performed only if necessary and with care to avoid frictional damage of the fragile nasal mucosa by using the most minimally invasive technique available. Testing should be aimed to avoid any unneeded pressure to any mucosal surface.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with EB and COVID-19 who are hospitalized, special care should be employed when applying cuffs for the measurement of blood pressure, securing intravenous lines, or intubating to avoid cutaneous and mucosal blistering and ulceration, with liberal use of lubricants (eg, petroleum jelly).</p><p></p><p class="headingAnchor" id="H56675661"><span class="h1">MANAGEMENT OF NEONATES</span><span class="headingEndMark"> — </span>The early management of neonates with epidermolysis bullosa (EB) should be undertaken in a neonatal or pediatric unit with the expertise, staffing, and resources necessary to manage extensive erosions or potential complications related to widespread skin sloughing [<a href="#rid12">12,13</a>]. Expert nursing care is key to successful treatment of neonates with EB. Coordination of a multidisciplinary team involved in in-hospital management is essential and includes training parents/caregivers and nonspecialist nurses at other centers and organizing the child's return home. They should not have heel prick tests performed at birth, as this carries the risk of degloving of the heel. Blood should be taken by venipuncture instead.</p><p>Newborns presenting with skin lesions suspicious of EB should be handled with extreme care. They should be placed on a thick foam pad and the pad should be used for transporting the infant (eg, from the bed to the caregiver's arms). Heat may induce blisters in some neonates with EB; the risks and benefits of using an incubator must be determined individually.</p><p>If suction is necessary, a soft catheter should be chosen and minimal suction pressure exerted [<a href="#rid14">14</a>]. In newborns with severe dystrophic epidermolysis bullosa (DEB), over-zealous suction can strip the mucosa, resulting in scarring and earlier development of pharyngeal strictures.</p><p>There is still a difference of opinion on whether it is best to teach parents/caregivers how to bathe their baby and change the dressings from birth or whether to try to delay bathing until lesions present at birth have healed. The problem with delaying this important bonding and teaching is that babies and parents/caregivers can become averse to future bathing, which then leads to apprehension about bathing and may result in increased infections. Small babies are easy to bathe in warmed bags of normal <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> in a baby bath, which is isotonic with the blood, thus avoiding stinging [<a href="#rid15">15</a>]. If delaying bathing is chosen, the erosions can be cleaned by gentle irrigation with warm sterile normal saline and covered with nonadherent dressings [<a href="#rid16">16</a>]. Dressings are changed on one limb at a time to prevent self-inflicted trauma from kicking the bare skin on the opposite limb if the infant is agitated during the change. (See <a class="local">'Wound dressing'</a> below.)</p><p>Disposable diapers can be used but should be lined with a soft material to reduce trauma from the elastic edges. Erosions on the diaper area can be protected by liberal application of a mixture of white soft paraffin and liquid paraffin in equal parts or petrolatum [<a href="#rid14">14</a>]. Specialized, nonadherent dressings (eg, Mepilex Transfer, Mepilex Lite) are also available for this purpose. More information is provided by <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.debra.org%2F&amp;token=ZAuWdG5s4GIvjFnkWRP6rBhDauAum10yKoDutiIm2iU%3D&amp;TOPIC_ID=15453" target="_blank">the patient support group website</a>. Clothing helps to prevent self-inflicted skin damage from kicking or rubbing. Clothes should be turned inside out to prevent skin damage from the seams.</p><p class="headingAnchor" id="H13245661"><span class="h1">SKIN AND WOUND CARE</span></p><p class="headingAnchor" id="H12936341"><span class="h2">Bathing</span><span class="headingEndMark"> — </span>Bathing in normal water is painful for patients with severe forms of epidermolysis bullosa (EB) and open wounds. In our clinical experience, pain is greatly reduced by bathing with salt water that approximates isotonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> for bathing. For neonates, warmed bags of normal saline may be used in small baby bathtubs. Normal saline baths can also be prepared by dissolving approximately one kg (two pounds) of pool salt in a full tub (approximately 40 gallons [160 L]) of warm water [<a href="#rid15">15</a>]. Pool salt is less expensive than table salt and available commercially. In one retrospective, observational study including 21 patients (11 with recessive dystrophic epidermolysis bullosa [RDEB]), saltwater baths significantly reduced pain and pain medication use in most patients [<a href="#rid17">17</a>]. Reduction of body odor and skin exudate were additional beneficial effects.</p><p class="headingAnchor" id="H2724935422"><span class="h2">Wound dressing</span><span class="headingEndMark"> — </span>Nonstick or nonadherent silicone dressings and foam dressings that absorb exudates are ideal as primary dressings for EB wounds. They can be covered with absorbent padding and left in place for several days. Using expensive nonstick dressings as a secondary layer is unnecessary, costly, and offers no additional benefit. Removal of adherent dressings can be facilitated by soaking in the bath, which is the easiest way to painlessly remove them. The recommended dressings for specific subtypes of EB are listed in the tables  (<a class="graphic graphic_table graphicRef87148 graphicRef87149 graphicRef87150" href="/d/graphic/87148.html" rel="external">table 4A-C</a>) [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/d/html/15912.html" rel="external">"Basic principles of wound management", section on 'Wound dressings'</a>.)</p><p>In patients with wounds covering large areas of the body, dressing change is laborious, time consuming, and may be painful [<a href="#rid18">18</a>]. The frequency of change depends upon the patient's preference, time availability, amount of exudate, and presence of infection. Wounds with bacterial colonization or frank infection may require more frequent changes and specific types of dressings  (<a class="graphic graphic_table graphicRef87151" href="/d/graphic/87151.html" rel="external">table 5</a>). (See <a class="local">'Prevention and management of infection'</a> below.)</p><p>In addition to tub soaks, measures to reduce the discomfort associated with wound care include [<a href="#rid16">16</a>] (see <a class="local">'Bathing'</a> above):</p><p class="bulletIndent1"><span class="glyph">●</span>Turning off fans before removing dressings to reduce pain from circulating air</p><p class="bulletIndent1"><span class="glyph">●</span>Cutting templates for dressing specific wounds or body areas</p><p class="bulletIndent1"><span class="glyph">●</span>Cutting all dressings before starting the dressing change</p><p class="bulletIndent1"><span class="glyph">●</span>Using tubular bandage rather than tape to cover dressings and hold them in place</p><p></p><p class="headingAnchor" id="H268520893"><span class="h2">Novel topical wound therapies</span></p><p class="headingAnchor" id="H565849755"><span class="h3">Topical gene therapy (beremagene geperpavec)</span><span class="headingEndMark"> — </span>In May 2023, <a class="drug drug_general" data-topicid="141539" href="/d/drug information/141539.html" rel="external">beremagene geperpavec</a> (B-VEC) was approved by the US Food and Drug Administration for the treatment of wounds in patients six months of age and older with dystrophic epidermolysis bullosa (DEB) due to variants in the type VII collagen alpha 1 chain gene (<em>COL7A1</em>) [<a href="#rid19">19</a>]. B-VEC is a replication-defective and nonintegrating, modified herpes simplex virus 1 vector that is topically applied to deliver a functional version of the <em>COL7A1</em> gene directly to skin cells. Treatment with B-VEC seeks to restore the production of type VII collagen in patients with DEB.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – B-VEC is applied to selected wounds in evenly spaced droplets once weekly [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – The efficacy of B-VEC was first evaluated in a phase 1/2, intrapatient, comparison trial in nine adult and pediatric patients with DEB [<a href="#rid20">20</a>]. At 12 weeks, complete wound closure (reduction in wound area from baseline ≥95 percent) was observed in 83 percent of the wounds treated with B-VEC compared with 14 percent of the wounds treated with placebo. In many cases, the wound-healing duration was longer than six months. The therapy was well tolerated with repeated dosing; adverse effects were mild and included fever, rash, and itching.</p><p></p><p class="bulletIndent1">In a subsequent intrapatient, phase 3, randomized trial, selected wound pairs in 31 patients with DEB (median age 16 years, range 1 to 44 years) were treated with B-VEC or placebo for six months [<a href="#rid21">21</a>]. At six months, complete wound healing occurred in 67 percent of the wounds treated with B-VEC compared with 22 percent of those treated with placebo. Sustained wound closure at three and six months after stopping treatment was observed in 50 percent of wounds exposed to B-VEC versus 7 percent of those exposed to placebo. Adverse events occurred in 58 percent of patients and were, in most cases, mild or moderate in severity (pruritus, chills). Cutaneous squamous cell carcinoma (cSCC) occurred in three patients at wound sites not exposed to B-VEC.</p><p></p><p class="headingAnchor" id="H3243428133"><span class="h3">Oleogel-S10 (birch triterpenes)</span><span class="headingEndMark"> — </span>In June 2022, the European Medicines Agency approved oleogel-S10 for the treatment of partial-thickness wounds associated with DEB and junctional epidermolysis bullosa (JEB) in patients six months and older [<a href="#rid22">22</a>]. Oleogel-S10 was also approved by the United Kingdom Medicines and Healthcare products Regulatory Agency in September 2022 and by the US Food and Drug Administration in December 2023 [<a href="#rid23">23</a>]. Oleogel-S10 is a sterile gel for topical use containing 10% <a class="drug drug_general" data-topicid="143742" href="/d/drug information/143742.html" rel="external">birch triterpenes</a> formulated with sunflower oil that acts at various stages of the wound-healing process, including modulation of inflammatory mediators, keratinocyte migration, and differentiation stimulation [<a href="#rid24">24</a>]. A phase 2 trial conducted in Europe demonstrated improved would healing in EB [<a href="#rid25">25</a>]. A subsequent large, international, phase 3 trial evaluated oleogel-S10 in 223 patients with DEB or JEB with a target partial-thickness wound 10 to 50 cm<sup>2</sup> in size and lasting 21 days to 9 months [<a href="#rid26">26</a>]. The primary outcome was the proportion of the target wound showing within 45 days. At 45 days, complete healing was achieved in 41 percent of target wounds in the oleogel-S10 group versus 29 percent in the vehicle group (relative risk [RR] 1.44, 95% CI 1.01-2.05; number needed to treat [NNT] 8). Adverse events (eg, increase in wound size or wound reopening) occurred with similar frequency in the active treatment and vehicle groups and were, in most cases, mild or moderate.</p><p class="headingAnchor" id="H1959133096"><span class="h2">Foot care</span><span class="headingEndMark"> — </span>Foot blistering from friction or minor trauma is common in all types of EB. While leaving the roof intact, rupture of blisters at their lowest point to allow gravitational drainage is recommended. Some prefer sterile scissors. In addition to regular wound care, podiatric consultation (preferably with a podiatrist with experience in EB) and use of molded orthotics, appropriate socks (eg, silver fiber socks, bamboo socks, double layer socks), and soft, ventilated, well-fitting footwear to minimize trauma and blistering is recommended. Shoes that have comfortable fit, appropriate length and width, rounded toe, plenty of room for the toes, flexibility, laces or straps to keep the foot from slipping, and flat or absent seams are recommended [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H3707630"><span class="h2">Prevention and management of infection</span><span class="headingEndMark"> — </span>Bacterial colonization of EB wounds, usually with <em>Staphylococcus</em> sp., <em>Streptococcus</em> sp., and <em>Pseudomonas aeruginosa</em>, is common [<a href="#rid28">28,29</a>]. Wounds that are "critically colonized" (ie, active multiplication of organisms without invasion) or frankly infected fail to heal [<a href="#rid30">30-33</a>]. In addition to nonhealing, clinical signs of critical colonization include increased exudate, red, friable tissue, debris, and smell. Wounds that are frankly infected present with increased size and depth, erythema/edema of surrounding skin, and increased exudate and smell. Systemic signs (eg, lymphadenopathy, fever, malaise) also may be present.</p><p>In critically colonized wounds, the bacterial load can be reduced with topical agents, including diluted bleach baths or compresses, topical antiseptics, and topical antibiotics [<a href="#rid34">34</a>]. Bacterial cultures of critically colonized wounds are not routinely performed. If required, cultures should be obtained before starting topical antimicrobial treatments.</p><p>Bleach baths are prepared by diluting 100 mL of bleach in an adult-sized bathtub. Patients are soaked in the bath for 10 minutes and then rinsed with lukewarm water.</p><p>Topical antiseptic agents include <a class="drug drug_general" data-topicid="9244" href="/d/drug information/9244.html" rel="external">chlorhexidine</a>, benzalkonium chloride, and <a class="drug drug_general" data-topicid="9890" href="/d/drug information/9890.html" rel="external">silver sulfadiazine</a>. However, prolonged use of silver preparations over large wounds may induce systemic silver toxicity (argyria) and a slate-gray metallic skin discoloration. (See  <a class="medical medical_review" href="/d/html/15912.html" rel="external">"Basic principles of wound management", section on 'Antiseptics and antimicrobial agents'</a> and  <a class="medical medical_review" href="/d/html/13509.html" rel="external">"Topical agents and dressings for local burn wound care", section on 'Antimicrobial agents'</a>.)</p><p>Topical antibiotics (eg, <a class="drug drug_general" data-topicid="9668" href="/d/drug information/9668.html" rel="external">mupirocin</a>, <a class="drug drug_general" data-topicid="8648" href="/d/drug information/8648.html" rel="external">fusidic acid</a>) should be used in moderation to avoid the emergence of antibiotic-resistant bacteria. If used, different agents should be rotated every two to six weeks to minimize the induction of bacterial resistance [<a href="#rid32">32</a>].</p><p>Wounds with frank infection usually require systemic antibiotics. The choice of antibiotic therapy should be based on bacterial culture and antibiogram results.</p><p class="headingAnchor" id="H71484649"><span class="h1">PAIN AND ITCH MANAGEMENT</span><span class="headingEndMark"> — </span>Pain is a constant feature of epidermolysis bullosa (EB) and an important management issue. Pain may be inherent (eg, from skin blisters and wounds, oral or corneal erosions, dental problems, etc) or elicited by bathing or dressing change. A comprehensive approach to EB pain management is summarized in the table  (<a class="graphic graphic_table graphicRef87169" href="/d/graphic/87169.html" rel="external">table 6</a>) [<a href="#rid35">35</a>].</p><p>For mild to moderate pain, analgesics (eg, paracetamol, <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a>) can be used alone or in conjunction with a nonsteroidal anti-inflammatory drug [<a href="#rid36">36</a>]. For more severe pain, opioids (eg, <a class="drug drug_general" data-topicid="9291" href="/d/drug information/9291.html" rel="external">codeine</a>, <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a>) or anxiolytics (eg, <a class="drug drug_general" data-topicid="9345" href="/d/drug information/9345.html" rel="external">diazepam</a>, <a class="drug drug_general" data-topicid="9573" href="/d/drug information/9573.html" rel="external">lorazepam</a>, <a class="drug drug_general" data-topicid="9650" href="/d/drug information/9650.html" rel="external">midazolam</a>) may be required [<a href="#rid35">35</a>]. <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">Gabapentin</a> and <a class="drug drug_general" data-topicid="9473" href="/d/drug information/9473.html" rel="external">pregabalin</a> may be used as adjuvant therapy for severe chronic pain [<a href="#rid34">34,37</a>]. (See  <a class="medical medical_review" href="/d/html/6254.html" rel="external">"Pain in children: Approach to pain assessment and overview of management principles"</a>.)</p><p>Opioids may be used topically to provide analgesia without adverse effects or induction of tolerance [<a href="#rid38">38</a>]. A preparation of 10 mg of <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> sulfate mixed with 15 g of hydrogel can be applied directly to open wounds at dressing changes. Nonaddictive topical cannabinoids are also in use by patients with EB, and they appear to reduce pain. However, clinical trials are necessary to determine their effectiveness.</p><p>Chronic pruritus is a prominent debilitating feature of EB [<a href="#rid39">39</a>]. Measures that may be helpful include antihistamines, antidepressants, and oral <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">gabapentin</a> or <a class="drug drug_general" data-topicid="9473" href="/d/drug information/9473.html" rel="external">pregabalin</a>.</p><p>In a small, eight-week, randomized trial of 14 patients with EB, serlopitant (an investigational oral neurokinin 1 antagonist) was not more effective than placebo in reducing the average itch score measured by an 11-point numeric rating scale [<a href="#rid40">40</a>]. However, a larger number of patients in the serlopitant group had an itch score reduced by ≥3 points compared with the placebo group. Due to these encouraging results, a larger, randomized trial of serlopitant for the treatment of pruritus in patients with EB is underway (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fstudy%2FNCT03836001&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSx2Mz1mAmiCDzFkn2PF3dIjHVX%2B0GhE4s1%2FwgUwW7ZS2A%3D%3D&amp;TOPIC_ID=15453" target="_blank">NCT03836001</a>).</p><p>Use of more than one agent may be needed. The daily application of emollients all over the skin, including unaffected areas, may also be beneficial. Oral pain can be reduced by rinsing the mouth with coating products (eg, <a class="drug drug_general" data-topicid="9953" href="/d/drug information/9953.html" rel="external">sucralfate</a>) or topical anesthetics [<a href="#rid41">41</a>].</p><p class="headingAnchor" id="H1169598427"><span class="h1">MANAGEMENT OF NUTRITIONAL COMPROMISE</span><span class="headingEndMark"> — </span>All patients with severe forms of epidermolysis bullosa (EB), particularly recessive dystrophic epidermolysis bullosa (RDEB) or junctional epidermolysis bullosa (JEB), have nutritional compromise and require nutritional support. Major causes of macro- and micronutrient deficiency include:</p><p class="bulletIndent1"><span class="glyph">●</span>Oral, oropharyngeal, and/or gastrointestinal complications (eg, ulcerations, strictures, painful defecation) that limit nutritional intake and/or nutrient absorption</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypercatabolic state due to chronic inflammation and infection of skin lesions</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nutrient loss due to loss of fluid and blood through cutaneous and mucosal lesions</p><p></p><p>Principles of evaluation and management of nutritional compromise in children with severe EB are discussed below [<a href="#rid42">42,43</a>].</p><p class="headingAnchor" id="H70257715"><span class="h2">Evaluation</span><span class="headingEndMark"> — </span>The nutritional status of children with severe forms of EB can be evaluated by the Tool to Help Identify Nutritional Compromise (THINC), a scoring system based upon the child's height, weight, and gain or loss of weight in the previous six months; gastroenterologic aspects (eg, tethered tongue, dysphagia, painful defecation, presence of a gastrostomy tube); and dermatologic aspects (eg, body surface area of denuded skin, skin infection) [<a href="#rid44">44</a>].</p><p class="headingAnchor" id="H70257722"><span class="h2">Nutritional support</span><span class="headingEndMark"> — </span>The aims of nutritional support include [<a href="#rid42">42,44,45</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Alleviating the stress associated with feeding difficulties</p><p class="bulletIndent1"><span class="glyph">●</span>Addressing macro- and micronutrient deficiencies (eg, hypoproteinemia, zinc or <a class="drug drug_general" data-topicid="9884" href="/d/drug information/9884.html" rel="external">selenium</a> deficiency)</p><p class="bulletIndent1"><span class="glyph">●</span>Promoting normal bowel function and alleviating painful defecation</p><p class="bulletIndent1"><span class="glyph">●</span>Promoting optimal growth rates for age, sex, and sexual maturation</p><p class="bulletIndent1"><span class="glyph">●</span>Promoting optimal immune status and wound healing</p><p class="bulletIndent1"><span class="glyph">●</span>Promoting mobility and quality of life</p><p></p><p>Breastfeeding is recommended for infants with EB. Supplementation with a more nutrient-dense formula may be necessary if breast feeding is not possible or weight gain is poor [<a href="#rid42">42</a>]. In infants with failure to thrive, temporary supplemented feeding using nasogastric (NG) tubes may be necessary. However, NG tubes should not be used for more than six to eight weeks, since they can cause mucosal trauma and scarring. (See  <a class="medical medical_review" href="/d/html/5013.html" rel="external">"Infant benefits of breastfeeding"</a> and  <a class="medical medical_review" href="/d/html/2874.html" rel="external">"Poor weight gain in children younger than two years in resource-abundant settings: Management"</a>.)</p><p>A gastrostomy tube (G-tube) may be beneficial for children with severe dystrophic epidermolysis bullosa (DEB) who require long-term supplementation [<a href="#rid46">46,47</a>]. (See  <a class="medical medical_review" href="/d/html/2583.html" rel="external">"Enteral feeding: Gastric versus post-pyloric", section on 'Gastric feeding'</a> and  <a class="medical medical_review" href="/d/html/15643.html" rel="external">"Overview of enteral nutrition in infants and children", section on 'Long-term needs'</a>.)</p><p>Placement of a G-tube is indicated in the following circumstances:</p><p class="bulletIndent1"><span class="glyph">●</span>Growth rate is lower than expected despite nutritional interventions</p><p class="bulletIndent1"><span class="glyph">●</span>Eating and drinking are aversive or painful</p><p class="bulletIndent1"><span class="glyph">●</span>Supplements or medications are refused</p><p class="bulletIndent1"><span class="glyph">●</span>Meal times are increasingly stressful and protracted</p><p class="bulletIndent1"><span class="glyph">●</span>Esophageal dilation does not alleviate the above issues</p><p></p><p>Patients with impaired gastric emptying, intractable gastro-esophageal reflux, and risk of aspiration may benefit from jejunal feeding with partially hydrolyzed feeds. (See  <a class="medical medical_review" href="/d/html/2583.html" rel="external">"Enteral feeding: Gastric versus post-pyloric", section on 'Post-pyloric feeding'</a>.)</p><p>Children receiving enteral feeding should be encouraged to maintain oral sucking and swallowing skills. Maintaining oral ability is important for social eating and development later in life.</p><p class="headingAnchor" id="H70257736"><span class="h2">Micronutrients</span><span class="headingEndMark"> — </span>The serum levels of micronutrients such as iron, zinc, <a class="drug drug_general" data-topicid="9884" href="/d/drug information/9884.html" rel="external">selenium</a>, vitamin B12, <a class="drug drug_general" data-topicid="10047" href="/d/drug information/10047.html" rel="external">vitamin A</a>, and folate should be checked at regular intervals (3 to 6 months for iron, 12 months for vitamins and trace elements)  (<a class="graphic graphic_table graphicRef87123" href="/d/graphic/87123.html" rel="external">table 3</a>) [<a href="#rid10">10</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Iron</strong> – Iron levels are frequently low in severe forms of EB due to chronic blood loss from cutaneous and visceral wounds and reduced intake. Iron deficiency usually is treated with oral iron; liquid formulations are generally more acceptable than tablets for young children. If oral iron is not tolerated or inadequately absorbed, iron should be given intravenously. (See  <a class="medical medical_review" href="/d/html/15647.html" rel="external">"Iron deficiency in infants and children &lt;12 years: Treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Calcium and vitamin D</strong> – Children with RDEB often have a low bone mineral density for age and increased risk of fractures [<a href="#rid48">48</a>]. (See <a class="local">'Osteopenia and osteoporosis'</a> below.)</p><p></p><p>Combined supplementation of calcium and vitamin D is required even in patients with adequate intake of milk and milk products, since chronic inflammation and infection can adversely affect bone turnover and gastrointestinal complications may interfere with absorption (see  <a class="medical medical_review" href="/d/html/14590.html" rel="external">"Vitamin D insufficiency and deficiency in children and adolescents", section on 'Malabsorption and other medical conditions'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Zinc</strong> – Zinc is essential for wound healing and immune function. Since most plasma zinc is bound to albumin, zinc levels may be low in patients with hypoalbuminemia. If supplementation is required for young children, the liquid form is preferable and daily doses may be split into two to reduce nausea. (See  <a class="medical medical_review" href="/d/html/5354.html" rel="external">"Zinc deficiency and supplementation in children", section on 'Recommended intake'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Selenium</strong> – Supplementation with <a class="drug drug_general" data-topicid="9884" href="/d/drug information/9884.html" rel="external">selenium</a> and <a class="drug drug_general" data-topicid="10109" href="/d/drug information/10109.html" rel="external">L-carnitine supplements</a> is indicated in children with RDEB [<a href="#rid42">42</a>]. In these patients, low levels of selenium and carnitine may play a role in the development of dilated cardiomyopathy [<a href="#rid49">49</a>]. (See  <a class="medical medical_review" href="/d/html/2585.html" rel="external">"Overview of dietary trace elements", section on 'Deficiency'</a> and  <a class="medical medical_review" href="/d/html/3516.html" rel="external">"Causes of dilated cardiomyopathy", section on 'Trace elements'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vitamins</strong> – If vitamin intake is not optimal, an age-appropriate multivitamin supplement is recommended. However, the total vitamin intake (particularly of <a class="drug drug_general" data-topicid="10047" href="/d/drug information/10047.html" rel="external">vitamin A</a>) should not exceed the recommended safe upper limits. In children with severe EB, vitamin supplementation up to 150 to 200 percent of normal national recommendations is considered safe [<a href="#rid42">42</a>]. Vitamin supplementation is given orally in most cases. Children with feeding difficulties or esophageal strictures may need intravenous supplementation. (See  <a class="medical medical_review" href="/d/html/2866.html" rel="external">"Dietary recommendations for toddlers and preschool and school-age children", section on 'Vitamin and mineral supplements'</a>.)</p><p></p><p class="headingAnchor" id="H7615964"><span class="h2">Related problems</span></p><p class="headingAnchor" id="H7616088"><span class="h3">Anemia</span><span class="headingEndMark"> — </span>In patients with EB, anemia develops as a result of chronic inflammation, blood loss from cutaneous and mucosal wounds, and malabsorption of iron and other micronutrients from the gastrointestinal tract [<a href="#rid50">50</a>]. (See  <a class="medical medical_review" href="/d/html/7149.html" rel="external">"Anemia of chronic disease/anemia of inflammation"</a> and  <a class="medical medical_review" href="/d/html/7150.html" rel="external">"Causes and diagnosis of iron deficiency and iron deficiency anemia in adults"</a>.)</p><p>Parenteral iron supplementation may be necessary for patients who are unable to tolerate oral iron supplements [<a href="#rid51">51</a>]. Treatment with erythropoietin plus parenteral iron may be beneficial in severely anemic patients [<a href="#rid52">52,53</a>]. Transfusions may be required for rapid correction of anemia. (See  <a class="medical medical_review" href="/d/html/7148.html" rel="external">"Treatment of iron deficiency anemia in adults", section on 'Intravenous iron'</a> and  <a class="medical medical_review" href="/d/html/7149.html" rel="external">"Anemia of chronic disease/anemia of inflammation", section on 'ESAs'</a>.)</p><p class="headingAnchor" id="H7616095"><span class="h3">Osteopenia and osteoporosis</span><span class="headingEndMark"> — </span>Bone mineral density is decreased in most patients with RDEB and JEB due to reduced mobility, poor nutritional status, and low 25-hydroxyvitamin D levels [<a href="#rid54">54-57</a>]. In a study of 72 patients (57 adults) from the Australasian Epidermolysis Bullosa Registry who underwent dual-energy x-ray absorptiometry (DXA) scan, the prevalence of osteoporosis was 75 percent among patients with RDEB and JEB. Fifty percent of patients with epidermolysis bullosa simplex (EBS) and 30 percent of those with dominant dystrophic epidermolysis bullosa (DDEB) had osteopenia [<a href="#rid56">56</a>].</p><p>Annual screening with DXA scans is suggested for detecting osteopenia and osteoporosis [<a href="#rid48">48,54</a>]. Studies have shown that even patients with EBS have a higher incidence of osteopenia and osteoporosis than age-matched controls, presumably because their exercise levels are usually chronically reduced by blistering of the feet [<a href="#rid55">55,56</a>]. (See  <a class="medical medical_review" href="/d/html/2046.html" rel="external">"Screening for osteoporosis in postmenopausal women and men"</a>.) </p><p>In patients with decreased bone density, calcium and vitamin D supplementation (oral or by intramuscular injection) should be commenced and the serum bone profile monitored. In patients who have experienced spinal crush fractures or other fractures, additional therapies (including <a class="drug drug_general" data-topicid="15575" href="/d/drug information/15575.html" rel="external">denosumab</a> and <a class="drug drug_general" data-topicid="9902" href="/d/drug information/9902.html" rel="external">zoledronic acid</a>) should be considered in conjunction with an endocrinologist. Bisphosphonates are not usually easily taken by patients with EB and esophageal problems unless they have a gastrostomy. If there is renal impairment as well and parathyroid hormone is raised, <a class="drug drug_general" data-topicid="9183" href="/d/drug information/9183.html" rel="external">calcitriol</a> is often needed. (See <a class="local">'Micronutrients'</a> above and  <a class="medical medical_review" href="/d/html/5804.html" rel="external">"Etiology and treatment of calcipenic rickets in children", section on 'Nutritional rickets'</a> and  <a class="medical medical_review" href="/d/html/5355.html" rel="external">"Bone health and calcium requirements in adolescents", section on 'Calcium intake'</a> and  <a class="medical medical_review" href="/d/html/2023.html" rel="external">"Calcium and vitamin D supplementation in osteoporosis"</a>.) </p><p class="headingAnchor" id="H2496529782"><span class="h1">GENETIC CONSULTATION</span><span class="headingEndMark"> — </span>Affected families should be offered genetic consultation so that they can better understand their reproductive risks and options, such as prenatal diagnosis and preimplantation genetic testing. Affected individuals and family members may benefit from updated genetic consultation prior to their reproductive years.</p><p class="headingAnchor" id="H251868425"><span class="h1">PREGNANCY AND CHILDBIRTH</span><span class="headingEndMark"> — </span>Only a few studies have reported the outcomes of pregnancy and childbirth in patients with epidermolysis bullosa (EB) [<a href="#rid58">58-60</a>]. This limited evidence suggests that females with EB, including the more severe subtypes, can have successful pregnancies and deliveries. Consensus-based guidelines that provide recommendations for improving the preconception, pregnancy, childbirth, and postpartum management of females affected with EB have been published [<a href="#rid61">61</a>]. They provide detailed guidance for the care of patients with EB who desire to plan a pregnancy. Main recommendations include:</p><p class="bulletIndent1"><span class="glyph">●</span>Discuss and evaluate vulvovaginal manifestations as part of routine care of a female patient with EB, dependent on EB subtype, and offer preconception genetic counseling</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Offer prenatal testing for couples at reproductive risk of severe forms of EB, including carriers of autosomal dominant subtypes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Engage a multidisciplinary team early during pregnancy for females with severe forms of EB</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Discuss mode of childbirth and prepare a birth plan</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Offer vaginal birth as the preferred mode of delivery for females with all EB subtypes</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Provide modified skin care during labor and epidural placement including padding of monitoring equipment, avoid prolonged pressure, use nonadhesive tape and dressings</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Avoid instrumental vaginal delivery to minimize local skin trauma</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Discuss breastfeeding and options to avoid nipple trauma</p><p></p><p class="headingAnchor" id="H71482543"><span class="h1">MANAGEMENT OF EXTRACUTANEOUS COMPLICATIONS</span><span class="headingEndMark"> — </span>The management of extracutaneous complications of severe forms of epidermolysis bullosa (EB) requires consultation with appropriate specialists. Modified approaches are often needed to avoid further tissue damage.</p><p class="headingAnchor" id="H70256810"><span class="h2">Ocular lesions</span><span class="headingEndMark"> — </span>Ocular involvement in EB ranges from mild conjunctival irritation to severe blistering and scarring of conjunctiva, cornea, and eyelids leading to symblepharon and progressive visual impairment  (<a class="graphic graphic_table graphicRef86396" href="/d/graphic/86396.html" rel="external">table 7</a>) [<a href="#rid62">62-65</a>]. (See  <a class="medical medical_review" href="/d/html/15449.html" rel="external">"Epidermolysis bullosa: Epidemiology, pathogenesis, classification, and clinical features", section on 'Eye'</a>.)</p><p>For conjunctival irritation, regular use of preservative-free ocular lubricants is generally sufficient. Corneal erosions are treated with antibiotic ointments. Less common approaches used in severe cases include the application of amniotic membranes or cell sheets derived from autologous oral or limbal epithelium and corneal transplants [<a href="#rid64">64</a>]. In junctional epidermolysis bullosa (JEB)-laryngo-onycho-cutaneous syndrome, where there is a higher risk of blindness from conjunctival inflammation, <a class="drug drug_general" data-topicid="10095" href="/d/drug information/10095.html" rel="external">thalidomide</a> has been successfully used in at least one patient [<a href="#rid66">66</a>].</p><p>Chronic blepharitis can result in cicatricial ectropion and exposure keratitis. Conservative treatment includes moisture chambers and topical lubricants. Patients who do not improve with conservative treatment may require full-thickness skin grafting to the upper eyelid.</p><p>A large proportion of children with EB has clinically significant refractive errors and strabismus requiring orthoptic and ophthalmic surveillance [<a href="#rid65">65</a>]. (See  <a class="medical medical_review" href="/d/html/6260.html" rel="external">"Refractive errors in children"</a> and  <a class="medical medical_review" href="/d/html/6269.html" rel="external">"Evaluation and management of strabismus in children"</a>.)</p><p class="headingAnchor" id="H71482647"><span class="h2">Oral and dental lesions</span></p><p class="headingAnchor" id="H71482672"><span class="h3">Oral hygiene</span><span class="headingEndMark"> — </span>Gentle tooth brushing with a soft, small brush is possible in all patients with EB, even those with severe mucosal involvement. Mouth rinses with normal <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> can be used for gentle cleaning of the mucosal surfaces.</p><p class="headingAnchor" id="H248826133"><span class="h3">Dental treatment</span><span class="headingEndMark"> — </span>A preventive program with strict oral hygiene instructions for patients and parents/caregivers along with frequent professional cleaning and <a class="drug drug_general" data-topicid="8462" href="/d/drug information/8462.html" rel="external">fluoride</a> therapy is of key importance [<a href="#rid67">67</a>].</p><p>Dental care should be provided with great caution to patients with JEB or recessive dystrophic epidermolysis bullosa (RDEB) who have severe mucosal fragility, varying degrees of ankyloglossia, vestibule obliteration, and microstomia.</p><p>These patients require a modified approach for dental treatments, which includes [<a href="#rid68">68-70</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Lubrication of lips, oral mucosa, gloves, and instruments with petroleum jelly, <a class="drug drug_general" data-topicid="8959" href="/d/drug information/8959.html" rel="external">glycerin</a>, or <a class="drug drug_general" data-topicid="10153" href="/d/drug information/10153.html" rel="external">methylcellulose</a></p><p class="bulletIndent1"><span class="glyph">●</span>Avoidance of contact of suction tips with mucosal surface</p><p class="bulletIndent1"><span class="glyph">●</span>Drainage or incision of oral bullae to avoid spreading</p><p class="bulletIndent1"><span class="glyph">●</span>Avoidance of lateral traction and compression to prevent tissue sloughing</p><p></p><p>Patients with generalized enamel hypoplasia may require staged restoration of dentition with full crowns with or without dental implants to improve appearance and feeding ability [<a href="#rid71">71</a>]. Impression taking may be cumbersome in patients with microstomia. Custom-made gel or acrylic application trays are usually needed.</p><p>Tooth extractions should be performed by atraumatic techniques (eg, mucosal incisions) to prevent the formation of bullae. Hemostasis is obtained by applying gentle pressure with gauze packs. Sutures may or may not be used.</p><p>Perioperative complications include mucosal sloughing or blistering. Post-operative complications are rare and healing of oral tissues including alveolar sockets generally occurs in one to two weeks.</p><p>Orthodontic treatment is generally tolerated by patients with EB [<a href="#rid69">69</a>]. In patients with RDEB and microstomia, serial extractions during the appropriate stage of dental development can prevent dental crowding.</p><p>Anesthesia for dental procedures is most often local. However, conscious sedation or general anesthesia may be necessary for more extensive procedures in patients with severe forms of EB. (See  <a class="medical medical_review" href="/d/html/6330.html" rel="external">"Procedural sedation in children: Approach"</a>.)</p><p class="headingAnchor" id="H6850928"><span class="h2">Delayed puberty</span><span class="headingEndMark"> — </span>Delayed onset of puberty and reduced pubertal growth is common in children with severe EB [<a href="#rid57">57</a>]. Abnormalities in the secretion of gonadotropin releasing hormone (GnRH), growth hormone (GH), and insulin-like growth factor-1 (IGF-1) result from a multiplicity of factors, including chronic inflammation and malnutrition [<a href="#rid48">48,72</a>].</p><p>If delayed puberty is suspected, basal serum levels of luteinizing hormone, follicle stimulating hormone, and estradiol (in girls) or testosterone (in boys) should be obtained. Bone age can be assessed by radiographs of the left hand and wrist. (See  <a class="medical medical_review" href="/d/html/5814.html" rel="external">"Approach to the patient with delayed puberty", section on 'Initial testing'</a>.)</p><p>Hormonal treatment for puberty induction should be evaluated on a case-by-case basis in collaboration with a pediatric endocrinologist. (See  <a class="medical medical_review" href="/d/html/5814.html" rel="external">"Approach to the patient with delayed puberty", section on 'Therapy'</a>.)</p><p class="headingAnchor" id="H1740852"><span class="h2">Esophageal strictures</span><span class="headingEndMark"> — </span>Esophageal strictures are a frequent complication and a major cause of poor nutrition in RDEB and JEB. They occur most often in the upper third of the esophagus and may be present even in the absence of dysphagia [<a href="#rid73">73</a>].</p><p>Esophageal strictures are managed by esophageal dilation using endoscopic balloon dilators or fluoroscopy-guided, over-the-guidewire hydrostatic balloon dilators [<a href="#rid74">74-76</a>]. (See  <a class="medical medical_review" href="/d/html/2270.html" rel="external">"Endoscopic interventions for nonmalignant esophageal strictures in adults"</a>.)</p><p>Multiple procedures are often required because of recurrence. In a retrospective, multicenter study of 125 patients observed over 17 years, patients experienced a median of two (interquartile range one to seven months) stricture episodes, with a median interval between dilations of seven months (interquartile range 4 to 12 months) [<a href="#rid77">77</a>].</p><p>Despite esophageal dilation, some patients present with significant failure to thrive and require the placement of a gastrostomy tube for supplemental enteral feeding [<a href="#rid74">74</a>]. These can be reversed later in life if the patient reaches a normal weight. (See  <a class="medical medical_review" href="/d/html/2583.html" rel="external">"Enteral feeding: Gastric versus post-pyloric", section on 'Gastric feeding'</a> and  <a class="medical medical_review" href="/d/html/15643.html" rel="external">"Overview of enteral nutrition in infants and children", section on 'Long-term needs'</a>.)</p><p class="headingAnchor" id="H1740859"><span class="h2">Mitten deformity</span><span class="headingEndMark"> — </span>Pseudosyndactyly or "mitten" deformity of the hands and feet is a major complication of RDEB, occurring in over 95 percent of affected patients [<a href="#rid78">78</a>]. Pseudosyndactyly results from repeated blistering and scarring of the hands that initially induces obliteration of the web spaces and with time leads to the encasement of the entire distal extremity in an epidermal cocoon  (<a class="graphic graphic_picture graphicRef86598" href="/d/graphic/86598.html" rel="external">picture 1</a>). (See  <a class="medical medical_review" href="/d/html/15449.html" rel="external">"Epidermolysis bullosa: Epidemiology, pathogenesis, classification, and clinical features", section on 'Severe recessive dystrophic epidermolysis bullosa'</a>.)</p><p>Surgery is indicated when loss of hand function compromises the patient's independence [<a href="#rid79">79</a>]. Ideally, surgery should be performed when the patient's skin, medical, and nutritional conditions are optimal. The aims of surgery include:</p><p class="bulletIndent1"><span class="glyph">●</span>Providing simple pinch grip and grasp, by releasing the first web space and flexion contractures</p><p class="bulletIndent1"><span class="glyph">●</span>Allowing independent finger movement, by releasing pseudosyndactyly</p><p class="bulletIndent1"><span class="glyph">●</span>Improving the appearance of the hand</p><p></p><p>Postoperative use of custom-made splints and hand therapy are important to maintain the benefits of surgery [<a href="#rid80">80</a>]. Patients are educated about measures to prevent the loss of web spaces such as using nonadherent bandages or dressings (eg, petroleum jelly gauze) and wearing rings [<a href="#rid79">79</a>]. However, despite optimal postoperative care, contractures recur within two to five years [<a href="#rid81">81</a>].</p><p>Repeat surgery is planned on a case-by-case basis. Since the thumb contributes to the majority of hand function, the release of the first web space alone produces significant functional improvement. Many patients can cope well merely with the release of the dominant thumb. There is an isolated report of successful use of CO<sub>2</sub> laser to treat pseudosyndactyly [<a href="#rid82">82</a>].</p><p>In a preclinical study using mouse models of RDEB, mice treated with oral <a class="drug drug_general" data-topicid="9574" href="/d/drug information/9574.html" rel="external">losartan</a> (an angiotensin II receptor blocker antihypertensive agent that inhibits the transforming growth factor-beta scarring pathway) did not develop mitten forepaw deformity and had significantly longer digits than the mice in the placebo group [<a href="#rid83">83</a>]. A phase 1/2 trial is underway in patients with RDEB in Germany (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrialsregister.eu%2Fctr-search%2Fsearch%3Fquery%3DEpidermolysis%2BBullosa%2BAND%2Blosartan&amp;token=2RV7ZayJD%2FOHGcQahlK4ZcJ92XFMxRaECdadpqSqNF0d4OaflM1KONlyMhNHV9inGaouZ4bZ13HnFL1SCBGUZUPEyTIjS%2B0hLy%2BZ2f9PW9Q2Bqjw%2Bru1o3j%2FcJq7O63r&amp;TOPIC_ID=15453" target="_blank">EudraCT Number: 2015-003670-32</a>).</p><p class="headingAnchor" id="H1740866"><span class="h2">Squamous cell carcinoma</span><span class="headingEndMark"> — </span>Squamous cell carcinoma (SCC) arising in chronic wounds is the most serious complication and a major cause of death for patients with RDEB [<a href="#rid84">84</a>]. Comprehensive clinical practice guidelines for the diagnosis and management of SCC in patients with EB have been provided by an international multidisciplinary group of experts, based upon the best available evidence and clinical experience [<a href="#rid85">85</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surveillance and diagnosis</strong> – At-risk patients with EB should have regular clinical surveillance for SCC. Full body skin examinations every three to six months are recommended between ages 10 and 16 and every three months after age 16. Digital pictures taken at each appointment may be useful for comparison during follow-up visits [<a href="#rid84">84</a>].</p><p></p><p class="bulletIndent1">Any skin areas that are suspicious for SCC (eg, nonhealing, painful wounds) should be biopsied for histopathologic examination  (<a class="graphic graphic_picture graphicRef86599 graphicRef86600" href="/d/graphic/86599.html" rel="external">picture 2A-B</a>). Suspicious areas include wounds that do not heal in four weeks or more, rapid wound growth resembling exuberant granulation tissue, deep ulcers with raised borders, hyperkeratotic areas in a wound, and abnormally painful wounds.</p><p></p><p class="bulletIndent1">Multiple biopsies should be taken from the edges of a lesion, and the position of each biopsy within the lesion should be carefully recorded with a clinical diagram or digital photograph. Biopsy specimen should be examined by an experienced pathologist, given the difficulty in distinguishing SCC from granulation tissue or pseudoepitheliomatous hyperplasia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgical treatment and staging</strong> – Wide local excision with 2 cm margins is considered the treatment of choice for SCCs confirmed by histopathologic examination. Mohs micrographic surgery and rush paraffin sections ("slow Mohs") are alternative methods that allow complete margin examination and a more precise removal of the tumor while preserving the uninvolved tissue [<a href="#rid86">86</a>]. Limitations to the use of Mohs surgery in patients with EB include the difficulty in tissue handling, due to the intrinsic fragility of EB skin, and in differentiating SCC from pseudoepitheliomatous hyperplasia in frozen sections [<a href="#rid86">86</a>]. (See  <a class="medical medical_review" href="/d/html/13708.html" rel="external">"Mohs surgery"</a>.)</p><p></p><p class="bulletIndent1">Preoperative localized imaging studies, including magnetic resonance imaging (MRI), computerized tomography (CT) scan, or ultrasonography, are helpful in assessing local invasion. Locally invasive lesions (eg, lesions involving vessels, nerves, tendons, or bones) that are not amenable to wide local excision may require amputation.</p><p></p><p class="bulletIndent1">Because of the aggressive nature of SCC associated with EB, patients with invasive tumors should undergo staging evaluation. Imaging studies of chest, abdomen, and pelvis are generally performed by ultrasonography, CT scan, or MRI. Positron emission tomography scans can also be used to determine the extent and presence of hematogenous or lymphatic metastases. (See  <a class="medical medical_review" href="/d/html/13713.html" rel="external">"Recognition and management of high-risk (aggressive) cutaneous squamous cell carcinoma", section on 'Staging'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonsurgical treatments</strong> – Patients with locally advanced or metastatic disease may be treated with adjunctive radiotherapy or chemotherapy. Radiotherapy may be useful to reduce the primary tumor size prior to surgical excision or may be used as a palliative treatment for the primary tumor if surgery is not feasible and for subcutaneous, lymph nodes and distant metastases [<a href="#rid87">87</a>]. Radiation doses as low as 2 Gy per fraction should be used in patients with EB to minimize the risk of severe desquamation and skin ulceration.</p><p></p><p class="bulletIndent1">Conventional chemotherapeutic agents, including <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a>, taxol, and <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, have been used in the past in a few patients with advanced SCC with some benefit [<a href="#rid88">88</a>]. <a class="drug drug_general" data-topicid="9209" href="/d/drug information/9209.html" rel="external">Cetuximab</a>, a monoclonal antibody against the epidermal growth factor receptor (EGFR), has been used successfully in a few patients with EB [<a href="#rid89">89,90</a>]. Other nonsurgical treatment modalities include electrochemotherapy [<a href="#rid91">91</a>] and photodynamic therapy [<a href="#rid92">92</a>].</p><p></p><p class="headingAnchor" id="H467686724"><span class="h2">Punch grafting for chronic ulcers</span><span class="headingEndMark"> — </span>Punch grafting has been successfully used in a few patients with laminin 332-deficient junctional epidermolysis bullosa non-Herlitz (JEB-nH) for the treatment of chronic, deep ulcers on the extremities [<a href="#rid93">93</a>]. This technique may potentially be useful in patients with RDEB as well.</p><p class="headingAnchor" id="H71485171"><span class="h1">EXPERIMENTAL THERAPIES</span><span class="headingEndMark"> — </span>Research related to the treatment of epidermolysis bullosa (EB) is focused on the development of new surgical techniques as well as on gene-, protein-, and cell-based molecular therapies targeting specific gene defects in severe forms of EB, such as recessive dystrophic epidermolysis bullosa (RDEB) and junctional epidermolysis bullosa Herlitz (JEB-H) [<a href="#rid4">4,94-99</a>]. New anti-inflammatory topical agents for several forms of EB are under investigation. (See  <a class="medical medical_review" href="/d/html/15449.html" rel="external">"Epidermolysis bullosa: Epidemiology, pathogenesis, classification, and clinical features", section on 'Molecular pathogenesis'</a>.)</p><p>Although most of these targeted approaches, including culturing/grafting revertant mosaic keratinocytes [<a href="#rid100">100</a>], gene editing/engineering, and inducible pluripotent stem cells [<a href="#rid101">101,102</a>], are still in a preclinical stage of development, some have been evaluated in small clinical trials [<a href="#rid5">5,84,94-99</a>].</p><p class="headingAnchor" id="H71485203"><span class="h2">Gene therapy</span><span class="headingEndMark"> — </span>Gene therapy strategies include genomic locus transfer, cDNA transfer, ex vivo gene transfer, and in vivo gene transfer [<a href="#rid6">6</a>]. Functional correction of gene expression by spliceosome-mediated ribonucleic acid (RNA) trans-splicing (SMaRT) appears to be promising for RDEB, epidermolysis bullosa simplex with muscular dystrophy (EBS-MD), and autosomal dominant epidermolysis bullosa simplex (EBS) [<a href="#rid103">103-107</a>].</p><p class="headingAnchor" id="H2089729555"><span class="h3">Cutaneous gene therapy</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Expanded autologous keratinocytes transduced with retroviral vector containing unmutated </strong><strong><em>COL7A1</em></strong><strong> (EB-101)</strong> – The safety and efficacy of genetically corrected autologous epidermal grafts for the treatment of RDEB is being evaluated in an ongoing phase 1/2 clinical trial (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fstudy%2FNCT01263379&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSyro4T%2FvzLnJNRsBhQGWi%2BmSmzyTuhhANuiyiiOzgBK9Q%3D%3D&amp;TOPIC_ID=15453" target="_blank">NCT01263379</a>), whose preliminary results have been published [<a href="#rid108">108</a>]. In this study, autologous RDEB keratinocytes isolated from biopsy samples were transduced with a retroviral vector containing full-length human <em>COL7A</em>, assembled into epidermal sheet grafts, and applied to six wounds on four patients with severe RDEB. The primary safety outcomes were recombinant viral infection, cancer, and autoimmune reaction. Expression of type VII collagen was assessed by immunofluorescence microscopy or immunoelectron microscopy on graft biopsy samples, and by level of wound healing at 3, 6, and 12 months after transplantation. Type VII collagen expression at the dermal-epidermal junction was demonstrated on the graft sites in 9 of 10 biopsy samples at three months and in 5 of 12 samples at 12 months. A 75 percent or greater wound healing was demonstrated in 20 of 24 grafts at one month and in 12 of 24 at 12 months. All grafts were well tolerated and no serious adverse events were reported. Transient tissue-bound and circulating antibodies to type VII collagen were detected in one patient.</p><p></p><p class="bulletIndent1">Based on the preliminary results of this trial [<a href="#rid108">108</a>], the US Food and Drug Administration and the European Medicines Agency have granted the orphan drug designation for the gene therapy using ex vivo-expanded autologous keratinocytes transduced with retroviral vector containing the <em>COL7A1</em> gene (also called EB-101) for patients with RDEB [<a href="#rid109">109</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Expanded autologous keratinocytes transduced with retroviral vector containing unmutated </strong><strong><em>LAMB3</em></strong> – Genetically modified autologous cultured skin grafts have been used for the treatment of a seven-year-old boy with generalized junctional epidermolysis bullosa (JEB) presenting with complete epidermal loss on approximately 80 percent of the total body surface area [<a href="#rid110">110</a>]. The skin grafts, obtained by culturing the patient's keratinocytes from a nonblistered area transduced with a retroviral vector containing the nonmutated <em>LAMB3</em> gene, were applied to all denuded body surfaces. One month after grafting, epidermal regeneration was stable and complete. During a follow-up period of 21 months, the regenerated epidermis adhered firmly to the underlying dermis, even after induced mechanical stress, and did not form blisters. The absence of blisters was confirmed by histopathologic examination of multiple skin biopsies taken at 4, 8, and 21 months after grafting.</p><p></p><p class="headingAnchor" id="H71485210"><span class="h2">Cell-based therapies</span><span class="headingEndMark"> — </span>Cell-based therapies include fibroblast therapy and bone marrow transplantation [<a href="#rid4">4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intradermal allogenic fibroblast injection</strong> – Type VII collagen is synthesized in culture by epidermal keratinocytes and dermal fibroblasts. Following studies in murine models of RDEB, it was hypothesized that the injection of normal fibroblasts in the dermis of patients with RDEB could restore collagen synthesis and reduce skin fragility. Because fibroblasts are similar to mesenchymal stromal cells and have a low potential to activate the host's immune system, they are ideal candidates for cell-based therapies for RDEB [<a href="#rid95">95</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a small, uncontrolled open study, five patients with RDEB received a single intradermal injection of allogenic fibroblasts [<a href="#rid111">111</a>]. Increased expression of type VII collagen at the dermal-epidermal junction was noted at two weeks and up to three months after the injection, although the allogeneic fibroblasts were not detectable at the injection site. The mechanisms underlying the upregulation of collagen synthesis in these patients is unknown and may involve the expression of cytokines such as the heparin binding-EGF-like growth factor (HB-EGF) [<a href="#rid112">112</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In the first randomized controlled study involving five adult patients with severe generalized RDEB, 38 symmetric wounds (with one wound in each pair serving as an untreated control) were randomized to local injections of cultured allogenic fibroblasts in a crystalloid suspension solution with 2% albumin or injections of suspension solution with 2% albumin alone [<a href="#rid113">113</a>]. All injected wounds healed more rapidly than noninjected wounds, without difference between the cultured allogenic fibroblasts and vehicle. In three patients, an increased type VII collagen expression at the dermoepidermal junction and the appearance of anchoring fibrils on electron microscopy examination was noted in both fibroblast and placebo injection sites.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A similar randomized controlled trial evaluated the effects of allogenic fibroblasts injection into the margins of chronic erosions in 11 patients with RDEB [<a href="#rid96">96</a>]. Twenty-nine erosions were randomized to either a single injection of fibroblasts or normal <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> vehicle. Fibroblast injections produced a statistically significant greater reduction in the erosion area, time to healing, and proportion of wounds healed than vehicle only at seven days, but for the rest of the study, there was no significant difference between the two groups.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stem cell therapy</strong> – Stem cell therapy with allogeneic bone marrow transplantation is based upon the observation that bone marrow pluripotent stem cells can reprogram to keratinocytes and home to the skin [<a href="#rid5">5,98,114-118</a>]. In a murine model of RDEB, donor cells producing type VII collagen were detected at the dermal-epidermal junction in the recipient's skin [<a href="#rid115">115</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Stem cell therapy has been evaluated in a small clinical trial including seven children with RDEB [<a href="#rid5">5</a>]. All children underwent immuno-myeloablative chemotherapy followed by allogenic stem-cell transplantation. Two children died from complications associated with the procedure. All the surviving children achieved improved wound healing and reduced blistering between 30 to 130 days after transplantation. Because of the high mortality associated with bone marrow transplantation with myeloablation, there is a need of further studies evaluating less aggressive, nonmyeloablative, preparative regimens in patients with EB. (See  <a class="medical medical_review" href="/d/html/3557.html" rel="external">"Preparative regimens for hematopoietic cell transplantation"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bone marrow allogenic, nonhematopoietic mesenchymal stem cells (MSCs) have also been shown to promote healing of chronic wounds and reduce the formation of new blisters after systemic administration in 14 patients with RDEB [<a href="#rid119">119</a>]. Treatment with a skin-derived allogenic MSC population (ATP-binding cassette subfamily B member 5 [ABCB5]<sup>+</sup> MSC) with immunomodulatory, anti-inflammatory, and tissue-healing properties was evaluated in a phase 1/2 trial in 18 patients with RDEB aged 4 to 36 years [<a href="#rid120">120</a>]. At 12 weeks, treatment was associated with reductions in the Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) score and Instrument for Scoring Clinical Outcome of Research for Epidermolysis Bullosa-clinician (iscorEB-c) score, as well as with a reduction of itch and pain. Treatment-related adverse events included mild lymphadenopathy in one patient and hypersensitivity reaction in two patients, all of which resolved with treatment withdrawal. Based on the results of this trial, ABCB5<sup>+</sup> MSCs, referred to as allo-APZ2-EB, has been granted orphan drug designation by the US Food and Drug Administration and the European Medicines Agency. A larger and longer-term randomized trial is needed to confirm the efficacy and safety of ABCB5<sup>+</sup> MSCs.</p><p></p><p class="headingAnchor" id="H63096321"><span class="h2">Protein replacement therapy</span><span class="headingEndMark"> — </span>Protein replacement therapy for RDEB has been evaluated in preclinical studies using animal models [<a href="#rid121">121</a>]. It consists in delivering recombinant type VII collagen, locally or systemically, to skin wounds where the protein is defective or missing [<a href="#rid95">95,122</a>]. The feasibility of recombinant protein therapy is supported by the observation that type VII collagen is long lived and the intradermal injection of human type VII collagen into mouse models of RDEB (<em>COL7A1</em> null mice) can reverse the blistering phenotype and restore the expression of type VII collagen at the basal membrane zone for several weeks [<a href="#rid123">123,124</a>].</p><p>A subsequent study showed that intravenously injected human recombinant type VII collagen homes to full thickness skin wounds of nude mice and to the skin of <em>COL7A1</em> null mice, incorporates into the dermoepidermal junction, and restores the anchoring fibrils and the dermal-epidermal adherence [<a href="#rid125">125</a>]. Although protein replacement therapy represents a promising pathway toward clinical application, further research is needed to determine the efficacy and safety of this approach for patients with RDEB [<a href="#rid126">126,127</a>].</p><p class="headingAnchor" id="H2186944338"><span class="h2">Premature termination codon read-through drugs</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">Gentamicin</a> and some newer medications are capable of enabling the skipping or ignoring of premature termination codon mutations in patients with recessive diseases. At least 25 percent of patients with RDEB have one or two premature termination codon mutations in the <em>COL7A1</em> gene. Almost 100 percent of these were misread in vitro by gentamicin, resulting in almost complete type VII collagen production in vitro. </p><p>A small, pilot study of topical and intradermal <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> was conducted in RDEB in which both treatments improved wound healing without affecting the kidneys or hearing [<a href="#rid128">128</a>]. Two open-label studies of intravenous gentamicin 7.5 mg/kg/day for 14 days were conducted in RDEB and JEB over three months. In the RDEB study, four patients with RDEB and nonsense mutations showed increased type VII collagen production and improved wound healing and clinical status with no toxicities [<a href="#rid129">129</a>]. In the JEB study, three patients who had nonsense mutations in either <em>LAMB3</em> or <em>LAMA3</em> had improved wound healing and function and neither ototoxicity nor nephrotoxicity after one and three months. The EBDASI overall activity score was reduced. No autoantibodies against laminin 332 developed [<a href="#rid130">130</a>].</p><p class="headingAnchor" id="H3335018136"><span class="h2">Readthrough therapy (intravenous gentamicin)</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">Gentamicin</a> has the property to induce ribosomal readthrough of premature termination codons, thus allowing the expression of the absent or deficient protein. Intravenous gentamicin has been used as a readthrough therapy for intermediate and severe JEB caused by nonsense variants in <em>LAMA3</em> and <em>LAMB3</em> and for EBS-MD (caused by a homozygous nonsense variant in <em>PLEC</em>) [<a href="#rid131">131,132</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In a clinical trial, five children, two with intermediate JEB and three with severe JEB and confirmed nonsense variants in <em>LAMA3</em> or <em>LAMB3</em> in one or two alleles, were treated with intravenous <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> 7.5 mg/kg daily for 14 days (low dose) or 10 mg/kg daily for 24 days (high dose) [<a href="#rid131">131</a>]. After treatment, all patients showed increased laminin 332 expression in the dermal-epidermal junction. At three months, eight of nine monitored wounds in patients receiving low-dose gentamicin and all monitored wounds in patients receiving high-dose gentamicin exhibited greater than 85 percent closure. No nephrotoxicity or ototoxicity was noted.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a single case report, a female patient with EBS-MD plectin deficiency due to a biallelic nonsense variant in <em>PLEC1</em> received intravenous <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> 7.5 mg/kg/day for 14 consecutive days in 2019 and 2020 [<a href="#rid132">132</a>]. Both treatments were followed by increased plectin protein expression lasting five months, with improvement of nasal mucosal lesions and respiratory and neuromuscular parameters. No nephrotoxic or ototoxic effects were noted.</p><p></p><p>The repurposed use of <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> for the treatment of JEB is promising. It may provide relief of symptoms and improve quality of life for patients with severe JEB [<a href="#rid133">133</a>]. However, limitations to the use of such therapy include its low readthrough efficiency (ie, modest increase in the production of the defective protein), requiring repeated high-dose treatments with increased potential for bacterial resistance, nephrotoxicity, and ototoxicity [<a href="#rid134">134</a>]. </p><p class="headingAnchor" id="H1259172899"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>The risk of death among patients with epidermolysis bullosa (EB) differs markedly by EB subtype in terms of specific cause and magnitude of risk [<a href="#rid135">135</a>]. Most children with EB who survive the first 12 to 24 months of life will live at least into adulthood if meticulous, aggressive medical care is provided. In particular, advances in wound care have greatly reduced the risk of death from sepsis in patients with extensive wounds.</p><p class="headingAnchor" id="H1896777633"><span class="h2">Epidermolysis bullosa simplex</span><span class="headingEndMark"> — </span>The prognosis for patients with localized epidermolysis bullosa simplex (EBS) is favorable. Patients have a normal life expectancy and in most cases are able to live a normal life. In contrast, patients with generalized EBS Dowling-Meara experience inflammatory flares throughout their life. Children with the rare, recessive forms of EBS (eg, autosomal recessive lethal acantholytic EBS, EBS-pyloric atresia with extensive aplasia cutis) usually do not survive beyond the first year of life.</p><p class="headingAnchor" id="H2503546350"><span class="h2">Junctional epidermolysis bullosa</span><span class="headingEndMark"> — </span>Most patients with junctional epidermolysis bullosa Herlitz (JEB-H) and junctional epidermolysis bullosa non-Herlitz (JEB-nH) do not survive past infancy [<a href="#rid135">135-137</a>]. In one study, 19 of 22 children with JEB-H died before age 1 [<a href="#rid136">136</a>]. Sepsis, failure to thrive, and respiratory failure are the major causes of death.</p><p class="headingAnchor" id="H1369575979"><span class="h2">Dystrophic epidermolysis bullosa</span><span class="headingEndMark"> — </span>With improved nutritional support, wound care, and management of complications, patients with recessive dystrophic epidermolysis bullosa (RDEB) usually survive to their early 30s to 40s. Metastatic squamous cell carcinoma and renal failure are major causes of death. Patients with dominant dystrophic epidermolysis bullosa (DDEB) generally survive to adulthood with few complications.</p><p class="headingAnchor" id="H1080336442"><span class="h2">Kindler epidermolysis bullosa</span><span class="headingEndMark"> — </span>Patients with Kindler epidermolysis bullosa (KEB) generally have a good prognosis. However, they have increased photosensitivity and are at risk of developing skin cancer, particularly squamous cell carcinoma [<a href="#rid138">138</a>]. (See  <a class="medical medical_review" href="/d/html/15510.html" rel="external">"Kindler epidermolysis bullosa", section on 'Prognosis and follow-up'</a>.)</p><p class="headingAnchor" id="H3961358860"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/131341.html" rel="external">"Society guideline links: Epidermolysis bullosa"</a>.)</p><p class="headingAnchor" id="H4199639246"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles</strong> – The management of patients with epidermolysis bullosa (EB) is largely supportive and involves a multidisciplinary team, usually composed of a dermatologist, an EB nurse, a primary care provider, an occupational therapist, a nutritionist, and a social worker. Specialty teams (eg, ophthalmology, nephrology, hematology, endocrinology, cardiology, pain management, plastic surgery, specialized dentistry) are consulted as needed. (See <a class="local">'Introduction'</a> above and <a class="local">'General principles'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of the neonate with epidermolysis bullosa</strong> – The early management of neonates with EB should be undertaken in a neonatal or pediatric unit with the expertise, staffing, and resources necessary to manage extensive erosions or potential complications related to widespread skin sloughing. Since heat may induce blisters, the risks and benefits of using an incubator must be determined individually. Bathing should be delayed until the lesions present at birth have healed. (See <a class="local">'Management of neonates'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Wound care</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dressing</strong> – Wounds should be dressed with nonadherent silicone dressings, foam dressings that absorb exudates, and nonadherent silicone-based tape  (<a class="graphic graphic_table graphicRef87148 graphicRef87149 graphicRef87150" href="/d/graphic/87148.html" rel="external">table 4A-C</a>). Diluted bleach baths or compresses, topical antiseptics, and topical antibiotics are used to reduce the bacterial load in wounds with critical bacterial colonization. Frankly infected wounds usually require systemic antibiotics. (See <a class="local">'Wound dressing'</a> above and <a class="local">'Prevention and management of infection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Novel topical therapies</strong> – Novel topical wound treatments include topical gene therapy with <a class="drug drug_general" data-topicid="141539" href="/d/drug information/141539.html" rel="external">beremagene geperpavec</a> (B-VEC; an inactive viral vector carrying a functional version of the <em>COL7A1</em> gene), approved in 2023 by the US Food and Drug Administration for the treatment of wounds in patients ≥6 months with dystrophic epidermolysis bullosa (DEB), and oleogel-S10 (a 10% <a class="drug drug_general" data-topicid="143742" href="/d/drug information/143742.html" rel="external">birch triterpenes</a> gel that promotes wound healing), approved in Europe and in the United Kingdom for the treatment of partial-thickness wounds in patients with DEB and junctional epidermolysis bullosa (JEB). (See <a class="local">'Topical gene therapy (beremagene geperpavec)'</a> above and <a class="local">'Oleogel-S10 (birch triterpenes)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pain control</strong> – Pain control is an important aspect of the management of patients with EB  (<a class="graphic graphic_table graphicRef87169" href="/d/graphic/87169.html" rel="external">table 6</a>). For mild to moderate pain, analgesics (eg, paracetamol, <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a>) can be used alone or in conjunction with a nonsteroidal anti-inflammatory drug. For severe pain, opioids or anxiolytics may be required. (See <a class="local">'Pain and itch management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nutrition</strong> – All patients with severe forms of EB have nutritional compromise and require nutritional support and ongoing weight checks, including home visits if necessary. Anemic patients require iron supplementation with or without erythropoietin. Calcium and vitamin D supplementation should be initiated in patients with evidence of osteopenia or osteoporosis. (See <a class="local">'Management of nutritional compromise'</a> above and <a class="local">'Related problems'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of extracutaneous manifestations</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ocular lesions</strong> – Conjunctival irritation, corneal erosions, and chronic blepharitis are generally treated conservatively with ocular lubricants and ointments. Severe cases may require autologous transplantation of limbal epithelium or allogenic corneal transplantation. (See <a class="local">'Ocular lesions'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Oral and dental lesions</strong> – Oral hygiene should be encouraged with gentle tooth brushing and normal <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> rinses. Dental treatments require a modified approach to limit local trauma and tissue damage. (See <a class="local">'Oral and dental lesions'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Esophageal strictures</strong> – Esophageal strictures are treated with fluoroscopy-guided hydrostatic balloon dilation. Recurrence is common, and repeated treatments may be needed. (See <a class="local">'Esophageal strictures'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pseudosyndactyly</strong> – Pseudosyndactyly with loss of hand function may be corrected by surgical release of the first web space and flexion contractures. (See <a class="local">'Mitten deformity'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cutaneous squamous cell carcinoma</strong> – Squamous cell carcinoma is treated with wide local excision or Mohs surgery. Locally invasive lesions may require amputations. (See <a class="local">'Squamous cell carcinoma'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – The risk of death among patients with EB differs markedly by EB subtype in terms of specific cause and magnitude of risk. Most children with EB who survive the first 12 to 24 months of life will live at least into adulthood if meticulous, aggressive medical care is provided. </p><p></p><p class="headingAnchor" id="H384754273"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Lizbeth Intong-Wheeler, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Fine JD, Eady RA, Bauer EA, et al. The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB. J Am Acad Dermatol 2008; 58:931.</a></li><li><a class="nounderline abstract_t">Fine JD. Inherited epidermolysis bullosa. Orphanet J Rare Dis 2010; 5:12.</a></li><li><a class="nounderline abstract_t">Intong LR, Murrell DF. Inherited epidermolysis bullosa: new diagnostic criteria and classification. Clin Dermatol 2012; 30:70.</a></li><li><a class="nounderline abstract_t">Uitto J, Has C, Bruckner-Tuderman L. Cell-based therapies for epidermolysis bullosa - from bench to bedside. J Dtsch Dermatol Ges 2012; 10:803.</a></li><li><a class="nounderline abstract_t">Wagner JE, Ishida-Yamamoto A, McGrath JA, et al. Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. N Engl J Med 2010; 363:629.</a></li><li><a class="nounderline abstract_t">Titeux M, Pendaries V, Hovnanian A. Gene therapy for recessive dystrophic epidermolysis bullosa. Dermatol Clin 2010; 28:361.</a></li><li><a class="nounderline abstract_t">El Hachem M, Zambruno G, Bourdon-Lanoy E, et al. Multicentre consensus recommendations for skin care in inherited epidermolysis bullosa. Orphanet J Rare Dis 2014; 9:76.</a></li><li><a class="nounderline abstract_t">Has C, El Hachem M, Bučková H, et al. Practical management of epidermolysis bullosa: consensus clinical position statement from the European Reference Network for Rare Skin Diseases. J Eur Acad Dermatol Venereol 2021; 35:2349.</a></li><li><a class="nounderline abstract_t">Fine JD, Johnson LB, Weiner M, Suchindran C. Impact of inherited epidermolysis bullosa on parental interpersonal relationships, marital status and family size. Br J Dermatol 2005; 152:1009.</a></li><li><a class="nounderline abstract_t">Martinez AE. Tests to monitor in patients with severe types of epidermolysis bullosa. Dermatol Clin 2010; 28:271, ix.</a></li><li><a class="nounderline abstract_t">Murrell DF, Lucky AW, Salas-Alanis JC, et al. Multidisciplinary care of epidermolysis bullosa during the COVID-19 pandemic-Consensus: Recommendations by an international panel of experts. J Am Acad Dermatol 2020; 83:1222.</a></li><li><a class="nounderline abstract_t">Saad R, Duipmans J, Yerlett N, et al. Neonatal Epidermolysis Bullosa: a clinical practice guideline. Br J Dermatol 2024.</a></li><li><a class="nounderline abstract_t">Retrosi C, Diociaiuti A, De Ranieri C, et al. Multidisciplinary care for patients with epidermolysis bullosa from birth to adolescence: experience of one Italian reference center. Ital J Pediatr 2022; 48:58.</a></li><li><a class="nounderline abstract_t">Denyer J. Management of severe blistering disorders. Semin Neonatol 2000; 5:321.</a></li><li><a class="nounderline abstract_t">Arbuckle HA. Bathing for individuals with epidermolysis bullosa. Dermatol Clin 2010; 28:265.</a></li><li><a class="nounderline abstract_t">Denyer JE. Wound management for children with epidermolysis bullosa. Dermatol Clin 2010; 28:257.</a></li><li><a class="nounderline abstract_t">Petersen BW, Arbuckle HA, Berman S. Effectiveness of saltwater baths in the treatment of epidermolysis bullosa. Pediatr Dermatol 2015; 32:60.</a></li><li><a class="nounderline abstract_t">Grocott P, Blackwell R, Weir H, Pillay E. Living in dressings and bandages: findings from workshops with people with Epidermolysis bullosa. Int Wound J 2013; 10:274.</a></li><li class="breakAll">Beremagene geperpavec-svdt biological suspension mixed with excipient gel for topical application. United States prescribing information. Revised May 2023. US Food and Drug Administration. https://www.fda.gov/media/168350/download (Accessed on May 23, 2023).</li><li><a class="nounderline abstract_t">Gurevich I, Agarwal P, Zhang P, et al. In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial. Nat Med 2022; 28:780.</a></li><li><a class="nounderline abstract_t">Guide SV, Gonzalez ME, Bağcı IS, et al. Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa. N Engl J Med 2022; 387:2211.</a></li><li class="breakAll">Oleogel-S10. European Medicines Agency (EMA) summary of product characteristics. Last updated June 2022. European Medicines Agency. https://www.ema.europa.eu/en/documents/product-information/filsuvez-epar-product-information_en.pdf (Accessed on June 22, 2023).</li><li class="breakAll">Birch triterpenes topical gel. US Food and Drug Administration (FDA) approved product information. Revised December 2023. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215064s000lbl.pdf (Accessed on January 02, 2024).</li><li><a class="nounderline abstract_t">Schwieger-Briel A, Ott H, Kiritsi D, et al. Mechanism of Oleogel-S10: A triterpene preparation for the treatment of epidermolysis bullosa. Dermatol Ther 2019; 32:e12983.</a></li><li><a class="nounderline abstract_t">Schwieger-Briel A, Kiritsi D, Schempp C, et al. Betulin-Based Oleogel to Improve Wound Healing in Dystrophic Epidermolysis Bullosa: A Prospective Controlled Proof-of-Concept Study. Dermatol Res Pract 2017; 2017:5068969.</a></li><li><a class="nounderline abstract_t">Kern JS, Sprecher E, Fernandez MF, et al. Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results from the phase III randomized double-blind phase of the EASE study. Br J Dermatol 2023; 188:12.</a></li><li><a class="nounderline abstract_t">Khan MT, O'Sullivan M, Faitli B, et al. Foot care in epidermolysis bullosa: evidence-based guideline. Br J Dermatol 2020; 182:593.</a></li><li><a class="nounderline abstract_t">Brandling-Bennett HA, Morel KD. Common wound colonizers in patients with epidermolysis bullosa. Pediatr Dermatol 2010; 27:25.</a></li><li><a class="nounderline abstract_t">Scollan ME, Levin LE, Lucky AW, et al. Characterization of wound microbes in epidermolysis bullosa: A focus on Pseudomonas aeruginosa. Pediatr Dermatol 2023; 40:863.</a></li><li><a class="nounderline abstract_t">Sibbald RG, Woo K, Ayello EA. Increased bacterial burden and infection: the story of NERDS and STONES. Adv Skin Wound Care 2006; 19:447.</a></li><li><a class="nounderline abstract_t">Howell-Jones RS, Wilson MJ, Hill KE, et al. A review of the microbiology, antibiotic usage and resistance in chronic skin wounds. J Antimicrob Chemother 2005; 55:143.</a></li><li><a class="nounderline abstract_t">Mellerio JE. Infection and colonization in epidermolysis bullosa. Dermatol Clin 2010; 28:267.</a></li><li><a class="nounderline abstract_t">Lara-Corrales I, Arbuckle A, Zarinehbaf S, Pope E. Principles of wound care in patients with epidermolysis bullosa. Pediatr Dermatol 2010; 27:229.</a></li><li><a class="nounderline abstract_t">Pope E, Lara-Corrales I, Mellerio J, et al. A consensus approach to wound care in epidermolysis bullosa. J Am Acad Dermatol 2012; 67:904.</a></li><li><a class="nounderline abstract_t">Goldschneider KR, Lucky AW. Pain management in epidermolysis bullosa. Dermatol Clin 2010; 28:273.</a></li><li><a class="nounderline abstract_t">Mellerio JE, Weiner M, Denyer JE, et al. Medical management of epidermolysis bullosa: Proceedings of the IInd International Symposium on Epidermolysis Bullosa, Santiago, Chile, 2005. Int J Dermatol 2007; 46:795.</a></li><li><a class="nounderline abstract_t">Allegaert K, Naulaers G. Gabapentin as part of multimodal analgesia in a newborn with epidermolysis bullosa. Paediatr Anaesth 2010; 20:972.</a></li><li><a class="nounderline abstract_t">Watterson G, Howard R, Goldman A. Peripheral opioids in inflammatory pain. Arch Dis Child 2004; 89:679.</a></li><li><a class="nounderline abstract_t">Cohn HI, Teng JM. Advancement in management of epidermolysis bullosa. Curr Opin Pediatr 2016; 28:507.</a></li><li><a class="nounderline abstract_t">Chiou AS, Choi S, Barriga M, et al. Phase 2 trial of a neurokinin-1 receptor antagonist for the treatment of chronic itch in patients with epidermolysis bullosa: A randomized clinical trial. J Am Acad Dermatol 2020; 82:1415.</a></li><li><a class="nounderline abstract_t">Marini I, Vecchiet F. Sucralfate: a help during oral management in patients with epidermolysis bullosa. J Periodontol 2001; 72:691.</a></li><li><a class="nounderline abstract_t">Haynes L. Nutrition for children with epidermolysis bullosa. Dermatol Clin 2010; 28:289.</a></li><li><a class="nounderline abstract_t">Zidorio AP, Dutra ES, Leão DO, Costa IM. Nutritional aspects of children and adolescents with epidermolysis bullosa: literature review. An Bras Dermatol 2015; 90:217.</a></li><li class="breakAll">Dystrophic Epidermolysis Bullosa Research Association. Clinical practice guidelines for nutrition support in infants and children with epidermolysis bullosa. http://www.debra.org.uk/uploads/resources/EB_Guidelines_Final_for_web.pdf (Accessed on December 03, 2012).</li><li><a class="nounderline abstract_t">Haynes L. Nutritional support for children with epidermolysis bullosa. Br J Nurs 2006; 15:1097.</a></li><li><a class="nounderline abstract_t">Colomb V, Bourdon-Lannoy E, Lambe C, et al. Nutritional outcome in children with severe generalized recessive dystrophic epidermolysis bullosa: a short- and long-term evaluation of gastrostomy and enteral feeding. Br J Dermatol 2012; 166:354.</a></li><li><a class="nounderline abstract_t">Mughal AZ, Subramanian T, Jones R, et al. Evaluating the use of laparoscopic-assisted gastrostomy tube feeding in children with epidermolysis bullosa: A single-center retrospective study. J Pediatr Surg 2022; 57:39.</a></li><li><a class="nounderline abstract_t">Martinez AE, Mellerio JE. Osteopenia and osteoporosis in epidermolysis bullosa. Dermatol Clin 2010; 28:353.</a></li><li><a class="nounderline abstract_t">Lara-Corrales I, Pope E. Dilated cardiomyopathy in epidermolysis bullosa. Dermatol Clin 2010; 28:347.</a></li><li><a class="nounderline abstract_t">Hwang SJE, Daniel BS, Fergie B, et al. Prevalence of anemia in patients with epidermolysis bullosa registered in Australia. Int J Womens Dermatol 2015; 1:37.</a></li><li><a class="nounderline abstract_t">Hubbard L, Haynes L, Sklar M, et al. The challenges of meeting nutritional requirements in children and adults with epidermolysis bullosa: proceedings of a multidisciplinary team study day. Clin Exp Dermatol 2011; 36:579.</a></li><li><a class="nounderline abstract_t">Kuo DJ, Bruckner AL, Jeng MR. Darbepoetin alfa and ferric gluconate ameliorate the anemia associated with recessive dystrophic epidermolysis bullosa. Pediatr Dermatol 2006; 23:580.</a></li><li><a class="nounderline abstract_t">Fridge JL, Vichinsky EP. Correction of the anemia of epidermolysis bullosa with intravenous iron and erythropoietin. J Pediatr 1998; 132:871.</a></li><li><a class="nounderline abstract_t">Fewtrell MS, Allgrove J, Gordon I, et al. Bone mineralization in children with epidermolysis bullosa. Br J Dermatol 2006; 154:959.</a></li><li><a class="nounderline abstract_t">Chen JS, Yang A, Murrell DF. Prevalence and pathogenesis of osteopenia and osteoporosis in epidermolysis bullosa: An evidence-based review. Exp Dermatol 2019; 28:1122.</a></li><li><a class="nounderline abstract_t">Kang M, Chen JSC, Radjenovic M, et al. An analysis of the prevalence of osteoporosis and osteopenia in patients with epidermolysis bullosa: A cross-sectional study. Exp Dermatol 2021; 30:1675.</a></li><li><a class="nounderline abstract_t">Wasserman H, Dumenigo A, Hornung L, et al. Prevalence of delayed puberty and low bone density in patients with epidermolysis bullosa: Insight from a large single center's experience. Pediatr Dermatol 2023; 40:100.</a></li><li><a class="nounderline abstract_t">Hanafusa T, Tamai K, Umegaki N, et al. The course of pregnancy and childbirth in three mothers with recessive dystrophic epidermolysis bullosa. Clin Exp Dermatol 2012; 37:10.</a></li><li><a class="nounderline abstract_t">Intong LRA, Choi SD, Shipman A, et al. Retrospective evidence on outcomes and experiences of pregnancy and childbirth in epidermolysis bullosa in Australia and New Zealand. Int J Womens Dermatol 2015; 1:26.</a></li><li><a class="nounderline abstract_t">Boria F, Maseda R, Martín-Cameán M, et al. Recessive Dystrophic Epidermolysis Bullosa and Pregnancy. Actas Dermosifiliogr (Engl Ed) 2019; 110:50.</a></li><li><a class="nounderline abstract_t">Greenblatt DT, Pillay E, Snelson K, et al. Recommendations on pregnancy, childbirth and aftercare in epidermolysis bullosa: a consensus-based guideline. Br J Dermatol 2022; 186:620.</a></li><li><a class="nounderline abstract_t">Tong L, Hodgkins PR, Denyer J, et al. The eye in epidermolysis bullosa. Br J Ophthalmol 1999; 83:323.</a></li><li><a class="nounderline abstract_t">Fine JD, Johnson LB, Weiner M, et al. Eye involvement in inherited epidermolysis bullosa: experience of the National Epidermolysis Bullosa Registry. Am J Ophthalmol 2004; 138:254.</a></li><li><a class="nounderline abstract_t">Figueira EC, Murrell DF, Coroneo MT. Ophthalmic involvement in inherited epidermolysis bullosa. Dermatol Clin 2010; 28:143.</a></li><li><a class="nounderline abstract_t">Smith KA, Jones SM, Nischal KK. Refractive and ocular motility findings in children with epidermolysis bullosa. Am Orthopt J 2009; 59:76.</a></li><li><a class="nounderline abstract_t">Strauss RM, Bäte J, Nischal KK, et al. A child with laryngo-onychocutaneous syndrome partially responsive to treatment with thalidomide. Br J Dermatol 2006; 155:1283.</a></li><li><a class="nounderline abstract_t">Dağ C, Bezgin T, Özalp N. Dental management of patients with epidermolysis bullosa. Oral Health Dent Manag 2014; 13:623.</a></li><li><a class="nounderline abstract_t">Krämer SM. Oral care and dental management for patients with epidermolysis bullosa. Dermatol Clin 2010; 28:303.</a></li><li><a class="nounderline abstract_t">Krämer SM, Serrano MC, Zillmann G, et al. Oral health care for patients with epidermolysis bullosa--best clinical practice guidelines. Int J Paediatr Dent 2012; 22 Suppl 1:1.</a></li><li><a class="nounderline abstract_t">Feijoo JF, Bugallo J, Limeres J, et al. Inherited epidermolysis bullosa: an update and suggested dental care considerations. J Am Dent Assoc 2011; 142:1017.</a></li><li><a class="nounderline abstract_t">Candel-Marti ME, Ata-Ali J, Peñarrocha-Oltra D, et al. Dental implants in patients with oral mucosal alterations: An update. Med Oral Patol Oral Cir Bucal 2011; 16:e787.</a></li><li><a class="nounderline abstract_t">Martinez AE, Allgrove J, Brain C. Growth and pubertal delay in patients with epidermolysis bullosa. Dermatol Clin 2010; 28:357.</a></li><li><a class="nounderline abstract_t">Guerra-Leal JD, Meester I, Cantu-Gonzalez JR, et al. The Importance of Esophagography in Patients With Recessive Dystrophic Epidermolysis Bullosa. AJR Am J Roentgenol 2016; 207:778.</a></li><li><a class="nounderline abstract_t">Mortell AE, Azizkhan RG. Epidermolysis bullosa: management of esophageal strictures and enteric access by gastrostomy. Dermatol Clin 2010; 28:311.</a></li><li><a class="nounderline abstract_t">Spiliopoulos S, Sabharwal T, Krokidis M, et al. Fluoroscopically guided dilation of esophageal strictures in patients with dystrophic epidermolysis bullosa: long-term results. AJR Am J Roentgenol 2012; 199:208.</a></li><li><a class="nounderline abstract_t">Alshammari J, Quesnel S, Pierrot S, Couloigner V. Endoscopic balloon dilatation of esophageal strictures in children. Int J Pediatr Otorhinolaryngol 2011; 75:1376.</a></li><li><a class="nounderline abstract_t">Pope E, Mansour M, Berseneva M, et al. Outcomes and Predictors for Re-stenosis of Esophageal Stricture in Epidermolysis Bullosa: A Multicenter Cohort Study. J Pediatr Gastroenterol Nutr 2020; 71:310.</a></li><li><a class="nounderline abstract_t">Fine JD, Johnson LB, Weiner M, et al. Pseudosyndactyly and musculoskeletal contractures in inherited epidermolysis bullosa: experience of the National Epidermolysis Bullosa Registry, 1986-2002. J Hand Surg Br 2005; 30:14.</a></li><li><a class="nounderline abstract_t">Bernardis C, Box R. Surgery of the hand in recessive dystrophic epidermolysis bullosa. Dermatol Clin 2010; 28:335.</a></li><li><a class="nounderline abstract_t">Formsma SA, Maathuis CB, Robinson PH, Jonkman MF. Postoperative hand treatment in children with recessive dystrophic epidermolysis bullosa. J Hand Ther 2008; 21:80.</a></li><li><a class="nounderline abstract_t">Campiglio GL, Pajardi G, Rafanelli G. A new protocol for the treatment of hand deformities in recessive dystrophic epidermolysis bullosa (13 cases). Ann Chir Main Memb Super 1997; 16:91.</a></li><li><a class="nounderline abstract_t">Hasegawa T, Ikeda S. Surgical management with CO2 laser for pseudosyndactyly in recessive dystrophic epidermolysis bullosa. J Dermatol 2014; 41:767.</a></li><li><a class="nounderline abstract_t">Nyström A, Thriene K, Mittapalli V, et al. Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms. EMBO Mol Med 2015; 7:1211.</a></li><li><a class="nounderline abstract_t">Venugopal SS, Murrell DF. Treatment of skin cancers in epidermolysis bullosa. Dermatol Clin 2010; 28:283.</a></li><li><a class="nounderline abstract_t">Mellerio JE, Robertson SJ, Bernardis C, et al. Management of cutaneous squamous cell carcinoma in patients with epidermolysis bullosa: best clinical practice guidelines. Br J Dermatol 2016; 174:56.</a></li><li><a class="nounderline abstract_t">Saxena A, Lee JB, Humphreys TR. Mohs micrographic surgery for squamous cell carcinoma associated with epidermolysis bullosa. Dermatol Surg 2006; 32:128.</a></li><li><a class="nounderline abstract_t">Bastin KT, Steeves RA, Richards MJ. Radiation therapy for squamous cell carcinoma in dystrophic epidermolysis bullosa: case reports and literature review. Am J Clin Oncol 1997; 20:55.</a></li><li><a class="nounderline abstract_t">Lentz SR, Raish RJ, Orlowski EP, Marion JM. Squamous cell carcinoma in epidermolysis bullosa. Treatment with systemic chemotherapy. Cancer 1990; 66:1276.</a></li><li><a class="nounderline abstract_t">Arnold AW, Bruckner-Tuderman L, Zuger C, Itin PH. Cetuximab therapy of metastasizing cutaneous squamous cell carcinoma in a patient with severe recessive dystrophic epidermolysis bullosa. Dermatology 2009; 219:80.</a></li><li><a class="nounderline abstract_t">Kim M, Li M, Intong LR, et al. Use of cetuximab as an adjuvant agent to radiotherapy and surgery in recessive dystrophic epidermolysis bullosa with squamous cell carcinoma. Br J Dermatol 2013; 169:208.</a></li><li><a class="nounderline abstract_t">Diociaiuti A, Rotunno R, El Hachem M, et al. Electrochemotherapy, a potential new treatment for the management of squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa: report of three cases. J Eur Acad Dermatol Venereol 2016; 30:1195.</a></li><li><a class="nounderline abstract_t">Souza CS, Felício LB, Bentley MV, et al. Topical photodynamic therapy for Bowen's disease of the digit in epidermolysis bullosa. Br J Dermatol 2005; 153:672.</a></li><li><a class="nounderline abstract_t">Yuen WY, Huizinga J, Jonkman MF. Punch grafting of chronic ulcers in patients with laminin-332-deficient, non-Herlitz junctional epidermolysis bullosa. J Am Acad Dermatol 2013; 68:93.</a></li><li><a class="nounderline abstract_t">Hsu CK, Wang SP, Lee JY, McGrath JA. Treatment of hereditary epidermolysis bullosa: updates and future prospects. Am J Clin Dermatol 2014; 15:1.</a></li><li><a class="nounderline abstract_t">Nyström A, Bruckner-Tuderman L, Kern JS. Cell- and protein-based therapy approaches for epidermolysis bullosa. Methods Mol Biol 2013; 961:425.</a></li><li><a class="nounderline abstract_t">Petrof G, Martinez-Queipo M, Mellerio JE, et al. Fibroblast cell therapy enhances initial healing in recessive dystrophic epidermolysis bullosa wounds: results of a randomized, vehicle-controlled trial. Br J Dermatol 2013; 169:1025.</a></li><li><a class="nounderline abstract_t">Conget P, Rodriguez F, Kramer S, et al. Replenishment of type VII collagen and re-epithelialization of chronically ulcerated skin after intradermal administration of allogeneic mesenchymal stromal cells in two patients with recessive dystrophic epidermolysis bullosa. Cytotherapy 2010; 12:429.</a></li><li><a class="nounderline abstract_t">Tolar J, Wagner JE. Management of severe epidermolysis bullosa by haematopoietic transplant: principles, perspectives and pitfalls. Exp Dermatol 2012; 21:896.</a></li><li><a class="nounderline abstract_t">Garcia-Doval I, Davila-Seijo P, Langan SM. Updated systematic review of randomized controlled trials of treatments for inherited forms of epidermolysis bullosa. Clin Exp Dermatol 2013; 38:92.</a></li><li><a class="nounderline abstract_t">Gostyński A, Pasmooij AM, Jonkman MF. Successful therapeutic transplantation of revertant skin in epidermolysis bullosa. J Am Acad Dermatol 2014; 70:98.</a></li><li><a class="nounderline abstract_t">Umegaki-Arao N, Pasmooij AM, Itoh M, et al. Induced pluripotent stem cells from human revertant keratinocytes for the treatment of epidermolysis bullosa. Sci Transl Med 2014; 6:264ra164.</a></li><li><a class="nounderline abstract_t">Sebastiano V, Zhen HH, Haddad B, et al. Human COL7A1-corrected induced pluripotent stem cells for the treatment of recessive dystrophic epidermolysis bullosa. Sci Transl Med 2014; 6:264ra163.</a></li><li><a class="nounderline abstract_t">Hengge UR. SMaRT technology enables gene expression repair in skin gene therapy. J Invest Dermatol 2008; 128:499.</a></li><li><a class="nounderline abstract_t">Murauer EM, Gache Y, Gratz IK, et al. Functional correction of type VII collagen expression in dystrophic epidermolysis bullosa. J Invest Dermatol 2011; 131:74.</a></li><li><a class="nounderline abstract_t">Wally V, Klausegger A, Koller U, et al. 5' trans-splicing repair of the PLEC1 gene. J Invest Dermatol 2008; 128:568.</a></li><li><a class="nounderline abstract_t">Wally V, Brunner M, Lettner T, et al. K14 mRNA reprogramming for dominant epidermolysis bullosa simplex. Hum Mol Genet 2010; 19:4715.</a></li><li><a class="nounderline abstract_t">Fritsch A, Spassov S, Elfert S, et al. Dominant-negative effects of COL7A1 mutations can be rescued by controlled overexpression of normal collagen VII. J Biol Chem 2009; 284:30248.</a></li><li><a class="nounderline abstract_t">Siprashvili Z, Nguyen NT, Gorell ES, et al. Safety and Wound Outcomes Following Genetically Corrected Autologous Epidermal Grafts in Patients With Recessive Dystrophic Epidermolysis Bullosa. JAMA 2016; 316:1808.</a></li><li class="breakAll">European Medicines Agency. Public summary of opinion on orphan designation: Ex-vivo-expanded autologous keratinocytes transduced with retroviral vector containing the COL7A1 gene for the treatment of epidermolysis bullosa. www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2017/03/WC500224892.pdf (Accessed on September 18, 2017).</li><li><a class="nounderline abstract_t">Hirsch T, Rothoeft T, Teig N, et al. Regeneration of the entire human epidermis using transgenic stem cells. Nature 2017; 551:327.</a></li><li><a class="nounderline abstract_t">Wong T, Gammon L, Liu L, et al. Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa. J Invest Dermatol 2008; 128:2179.</a></li><li><a class="nounderline abstract_t">Uitto J. Cell-based therapy for RDEB: how does it work? J Invest Dermatol 2011; 131:1597.</a></li><li><a class="nounderline abstract_t">Venugopal SS, Yan W, Frew JW, et al. A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosa. J Am Acad Dermatol 2013; 69:898.</a></li><li><a class="nounderline abstract_t">Kiuru M, Itoh M, Cairo MS, Christiano AM. Bone marrow stem cell therapy for recessive dystrophic epidermolysis bullosa. Dermatol Clin 2010; 28:371.</a></li><li><a class="nounderline abstract_t">Tolar J, Ishida-Yamamoto A, Riddle M, et al. Amelioration of epidermolysis bullosa by transfer of wild-type bone marrow cells. Blood 2009; 113:1167.</a></li><li><a class="nounderline abstract_t">Tolar J, Xia L, Riddle MJ, et al. Induced pluripotent stem cells from individuals with recessive dystrophic epidermolysis bullosa. J Invest Dermatol 2011; 131:848.</a></li><li><a class="nounderline abstract_t">Tolar J, Mehta PA, Walters MC. Hematopoietic cell transplantation for nonmalignant disorders. Biol Blood Marrow Transplant 2012; 18:S166.</a></li><li><a class="nounderline abstract_t">Tolar J, Wagner JE. Allogeneic blood and bone marrow cells for the treatment of severe epidermolysis bullosa: repair of the extracellular matrix. Lancet 2013; 382:1214.</a></li><li><a class="nounderline abstract_t">El-Darouti M, Fawzy M, Amin I, et al. Treatment of dystrophic epidermolysis bullosa with bone marrow non-hematopoeitic stem cells: a randomized controlled trial. Dermatol Ther 2016; 29:96.</a></li><li><a class="nounderline abstract_t">Kiritsi D, Dieter K, Niebergall-Roth E, et al. Clinical trial of ABCB5+ mesenchymal stem cells for recessive dystrophic epidermolysis bullosa. JCI Insight 2021; 6.</a></li><li><a class="nounderline abstract_t">Bruckner-Tuderman L, McGrath JA, Robinson EC, Uitto J. Animal models of epidermolysis bullosa: update 2010. J Invest Dermatol 2010; 130:1485.</a></li><li><a class="nounderline abstract_t">Uitto J, Christiano AM, McLean WH, McGrath JA. Novel molecular therapies for heritable skin disorders. J Invest Dermatol 2012; 132:820.</a></li><li><a class="nounderline abstract_t">Woodley DT, Keene DR, Atha T, et al. Injection of recombinant human type VII collagen restores collagen function in dystrophic epidermolysis bullosa. Nat Med 2004; 10:693.</a></li><li><a class="nounderline abstract_t">Remington J, Wang X, Hou Y, et al. Injection of recombinant human type VII collagen corrects the disease phenotype in a murine model of dystrophic epidermolysis bullosa. Mol Ther 2009; 17:26.</a></li><li><a class="nounderline abstract_t">Kim JY, Lee TR, Lee AY. Reduced WIF-1 expression stimulates skin hyperpigmentation in patients with melasma. J Invest Dermatol 2013; 133:191.</a></li><li><a class="nounderline abstract_t">Bruckner-Tuderman L. Can type VII collagen injections cure dystrophic epidermolysis bullosa? Mol Ther 2009; 17:6.</a></li><li><a class="nounderline abstract_t">Hovnanian A. Systemic protein therapy for recessive dystrophic epidermolysis bullosa: how far are we from clinical translation? J Invest Dermatol 2013; 133:1719.</a></li><li><a class="nounderline abstract_t">Kwong A, Cogan J, Hou Y, et al. Gentamicin Induces Laminin 332 and Improves Wound Healing in Junctional Epidermolysis Bullosa Patients with Nonsense Mutations. Mol Ther 2020; 28:1327.</a></li><li><a class="nounderline abstract_t">Woodley D, Kwong A, Cogan J, et al. 1021 Intravenous gentamicin therapy for recessive dystrophic epidermolysis bullosa patients harboring nonsense mutations. J Invest Dermatol 2019; 139:S176.</a></li><li><a class="nounderline abstract_t">Hao M, Antaya R, Cogan J, et al. 861 Intravenous gentamicin therapy for junctional epidermolysis bullosa patients harboring nonsense mutations. J Invest Dermatol 2020; 140:S112.</a></li><li><a class="nounderline abstract_t">Mosallaei D, Hao M, Antaya RJ, et al. Molecular and Clinical Outcomes After Intravenous Gentamicin Treatment for Patients With Junctional Epidermolysis Bullosa Caused by Nonsense Variants. JAMA Dermatol 2022; 158:366.</a></li><li><a class="nounderline abstract_t">Martínez-Santamaría L, Maseda R, de Arriba MDC, et al. Evaluation of Systemic Gentamicin as Translational Readthrough Therapy for a Patient With Epidermolysis Bullosa Simplex With Muscular Dystrophy Owing to PLEC1 Pathogenic Nonsense Variants. JAMA Dermatol 2022; 158:439.</a></li><li><a class="nounderline abstract_t">Hammersen J, Neuner A, Wild F, Schneider H. Attenuation of Severe Generalized Junctional Epidermolysis Bullosa by Systemic Treatment with Gentamicin. Dermatology 2019; 235:315.</a></li><li><a class="nounderline abstract_t">Bolling MC, Has C, Bruckner AL. Understanding the Potential Promise and Pitfalls of Intravenous Gentamicin as a Therapy for Epidermolysis Bullosa. JAMA Dermatol 2022; 158:356.</a></li><li><a class="nounderline abstract_t">Fine JD, Johnson LB, Weiner M, Suchindran C. Cause-specific risks of childhood death in inherited epidermolysis bullosa. J Pediatr 2008; 152:276.</a></li><li><a class="nounderline abstract_t">Yuen WY, Duipmans JC, Molenbuur B, et al. Long-term follow-up of patients with Herlitz-type junctional epidermolysis bullosa. Br J Dermatol 2012; 167:374.</a></li><li><a class="nounderline abstract_t">Kho YC, Rhodes LM, Robertson SJ, et al. Epidemiology of epidermolysis bullosa in the antipodes: the Australasian Epidermolysis Bullosa Registry with a focus on Herlitz junctional epidermolysis bullosa. Arch Dermatol 2010; 146:635.</a></li><li><a class="nounderline abstract_t">Lai-Cheong JE, McGrath JA. Kindler syndrome. Dermatol Clin 2010; 28:119.</a></li></ol></div><div id="topicVersionRevision">Topic 15453 Version 33.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18374450" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20507631" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Inherited epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22137229" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Inherited epidermolysis bullosa: new diagnostic criteria and classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23107326" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Cell-based therapies for epidermolysis bullosa - from bench to bedside.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20818854" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Bone marrow transplantation for recessive dystrophic epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20447504" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Gene therapy for recessive dystrophic epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24884811" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Multicentre consensus recommendations for skin care in inherited epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34545960" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Practical management of epidermolysis bullosa: consensus clinical position statement from the European Reference Network for Rare Skin Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15888161" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Impact of inherited epidermolysis bullosa on parental interpersonal relationships, marital status and family size.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20447491" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Tests to monitor in patients with severe types of epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32682031" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Multidisciplinary care of epidermolysis bullosa during the COVID-19 pandemic-Consensus: Recommendations by an international panel of experts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38175636" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Neonatal Epidermolysis Bullosa: a clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35414096" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Multidisciplinary care for patients with epidermolysis bullosa from birth to adolescence: experience of one Italian reference center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11032716" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Management of severe blistering disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20447489" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Bathing for individuals with epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20447488" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Wound management for children with epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25644039" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Effectiveness of saltwater baths in the treatment of epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22487531" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Living in dressings and bandages: findings from workshops with people with Epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22487531" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Living in dressings and bandages: findings from workshops with people with Epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35347281" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36516090" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36516090" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36516090" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31168940" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Mechanism of Oleogel-S10: A triterpene preparation for the treatment of epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28611842" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Betulin-Based Oleogel to Improve Wound Healing in Dystrophic Epidermolysis Bullosa: A Prospective Controlled Proof-of-Concept Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36689495" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results from the phase III randomized double-blind phase of the EASE study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31397882" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Foot care in epidermolysis bullosa: evidence-based guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20199405" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Common wound colonizers in patients with epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37364926" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Characterization of wound microbes in epidermolysis bullosa: A focus on Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17008815" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Increased bacterial burden and infection: the story of NERDS and STONES.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15649989" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A review of the microbiology, antibiotic usage and resistance in chronic skin wounds.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20447490" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Infection and colonization in epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20403117" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Principles of wound care in patients with epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22387035" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A consensus approach to wound care in epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20447492" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Pain management in epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17651159" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Medical management of epidermolysis bullosa: Proceedings of the IInd International Symposium on Epidermolysis Bullosa, Santiago, Chile, 2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20849513" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Gabapentin as part of multimodal analgesia in a newborn with epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15210505" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Peripheral opioids in inflammatory pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27386970" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Advancement in management of epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31541747" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Phase 2 trial of a neurokinin-1 receptor antagonist for the treatment of chronic itch in patients with epidermolysis bullosa: A randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11394407" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Sucralfate: a help during oral management in patients with epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20447494" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Nutrition for children with epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25830992" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Nutritional aspects of children and adolescents with epidermolysis bullosa: literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25830992" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Nutritional aspects of children and adolescents with epidermolysis bullosa: literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17170656" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Nutritional support for children with epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21895617" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Nutritional outcome in children with severe generalized recessive dystrophic epidermolysis bullosa: a short- and long-term evaluation of gastrostomy and enteral feeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34876295" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Evaluating the use of laparoscopic-assisted gastrostomy tube feeding in children with epidermolysis bullosa: A single-center retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20447502" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Osteopenia and osteoporosis in epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20447501" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Dilated cardiomyopathy in epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28491953" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Prevalence of anemia in patients with epidermolysis bullosa registered in Australia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21671991" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The challenges of meeting nutritional requirements in children and adults with epidermolysis bullosa: proceedings of a multidisciplinary team study day.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17156003" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Darbepoetin alfa and ferric gluconate ameliorate the anemia associated with recessive dystrophic epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9602203" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Correction of the anemia of epidermolysis bullosa with intravenous iron and erythropoietin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16634901" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Bone mineralization in children with epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30118182" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Prevalence and pathogenesis of osteopenia and osteoporosis in epidermolysis bullosa: An evidence-based review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33347654" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : An analysis of the prevalence of osteoporosis and osteopenia in patients with epidermolysis bullosa: A cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36161732" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Prevalence of delayed puberty and low bone density in patients with epidermolysis bullosa: Insight from a large single center's experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22007850" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The course of pregnancy and childbirth in three mothers with recessive dystrophic epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28491951" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Retrospective evidence on outcomes and experiences of pregnancy and childbirth in epidermolysis bullosa in Australia and New Zealand.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29203033" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Recessive Dystrophic Epidermolysis Bullosa and Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34687549" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Recommendations on pregnancy, childbirth and aftercare in epidermolysis bullosa: a consensus-based guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10365041" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : The eye in epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15289135" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Eye involvement in inherited epidermolysis bullosa: experience of the National Epidermolysis Bullosa Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19945628" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Ophthalmic involvement in inherited epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21149192" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Refractive and ocular motility findings in children with epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17107403" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : A child with laryngo-onychocutaneous syndrome partially responsive to treatment with thalidomide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25284524" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Dental management of patients with epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20447495" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Oral care and dental management for patients with epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22937908" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Oral health care for patients with epidermolysis bullosa--best clinical practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21881067" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Inherited epidermolysis bullosa: an update and suggested dental care considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21196861" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Dental implants in patients with oral mucosal alterations: An update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20447503" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Growth and pubertal delay in patients with epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27384758" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : The Importance of Esophagography in Patients With Recessive Dystrophic Epidermolysis Bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20447496" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Epidermolysis bullosa: management of esophageal strictures and enteric access by gastrostomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22733914" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Fluoroscopically guided dilation of esophageal strictures in patients with dystrophic epidermolysis bullosa: long-term results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21889217" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Endoscopic balloon dilatation of esophageal strictures in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32833391" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Outcomes and Predictors for Re-stenosis of Esophageal Stricture in Epidermolysis Bullosa: A Multicenter Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15620486" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Pseudosyndactyly and musculoskeletal contractures in inherited epidermolysis bullosa: experience of the National Epidermolysis Bullosa Registry, 1986-2002.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20447499" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Surgery of the hand in recessive dystrophic epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18215755" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Postoperative hand treatment in children with recessive dystrophic epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9259950" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : A new protocol for the treatment of hand deformities in recessive dystrophic epidermolysis bullosa (13 cases).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25041083" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Surgical management with CO2 laser for pseudosyndactyly in recessive dystrophic epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26194911" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20447493" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Treatment of skin cancers in epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26302137" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Management of cutaneous squamous cell carcinoma in patients with epidermolysis bullosa: best clinical practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16393614" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Mohs micrographic surgery for squamous cell carcinoma associated with epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9020289" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Radiation therapy for squamous cell carcinoma in dystrophic epidermolysis bullosa: case reports and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2205357" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Squamous cell carcinoma in epidermolysis bullosa. Treatment with systemic chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19439919" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Cetuximab therapy of metastasizing cutaneous squamous cell carcinoma in a patient with severe recessive dystrophic epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23398414" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Use of cetuximab as an adjuvant agent to radiotherapy and surgery in recessive dystrophic epidermolysis bullosa with squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25758658" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Electrochemotherapy, a potential new treatment for the management of squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa: report of three cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16120168" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Topical photodynamic therapy for Bowen's disease of the digit in epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22633040" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Punch grafting of chronic ulcers in patients with laminin-332-deficient, non-Herlitz junctional epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24402870" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Treatment of hereditary epidermolysis bullosa: updates and future prospects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23325662" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Cell- and protein-based therapy approaches for epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24032424" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Fibroblast cell therapy enhances initial healing in recessive dystrophic epidermolysis bullosa wounds: results of a randomized, vehicle-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20230217" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Replenishment of type VII collagen and re-epithelialization of chronically ulcerated skin after intradermal administration of allogeneic mesenchymal stromal cells in two patients with recessive dystrophic epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23016552" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Management of severe epidermolysis bullosa by haematopoietic transplant: principles, perspectives and pitfalls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22731863" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Updated systematic review of randomized controlled trials of treatments for inherited forms of epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24176523" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Successful therapeutic transplantation of revertant skin in epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25429057" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Induced pluripotent stem cells from human revertant keratinocytes for the treatment of epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25429056" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Human COL7A1-corrected induced pluripotent stem cells for the treatment of recessive dystrophic epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18268535" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : SMaRT technology enables gene expression repair in skin gene therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20720561" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Functional correction of type VII collagen expression in dystrophic epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17989727" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : 5' trans-splicing repair of the PLEC1 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20861136" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : K14 mRNA reprogramming for dominant epidermolysis bullosa simplex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19726672" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Dominant-negative effects of COL7A1 mutations can be rescued by controlled overexpression of normal collagen VII.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27802546" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Safety and Wound Outcomes Following Genetically Corrected Autologous Epidermal Grafts in Patients With Recessive Dystrophic Epidermolysis Bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27802546" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Safety and Wound Outcomes Following Genetically Corrected Autologous Epidermal Grafts in Patients With Recessive Dystrophic Epidermolysis Bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29144448" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Regeneration of the entire human epidermis using transgenic stem cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18385758" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21753764" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Cell-based therapy for RDEB: how does it work?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24075228" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20447506" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Bone marrow stem cell therapy for recessive dystrophic epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18955559" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Amelioration of epidermolysis bullosa by transfer of wild-type bone marrow cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21124339" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Induced pluripotent stem cells from individuals with recessive dystrophic epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22226101" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Hematopoietic cell transplantation for nonmalignant disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24095195" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Allogeneic blood and bone marrow cells for the treatment of severe epidermolysis bullosa: repair of the extracellular matrix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26439431" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Treatment of dystrophic epidermolysis bullosa with bone marrow non-hematopoeitic stem cells: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34665781" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Clinical trial of ABCB5+ mesenchymal stem cells for recessive dystrophic epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20463671" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Animal models of epidermolysis bullosa: update 2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22158553" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Novel molecular therapies for heritable skin disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15195089" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Injection of recombinant human type VII collagen restores collagen function in dystrophic epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19018253" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Injection of recombinant human type VII collagen corrects the disease phenotype in a murine model of dystrophic epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22951732" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Reduced WIF-1 expression stimulates skin hyperpigmentation in patients with melasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19116634" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Can type VII collagen injections cure dystrophic epidermolysis bullosa?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23760051" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Systemic protein therapy for recessive dystrophic epidermolysis bullosa: how far are we from clinical translation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32222156" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Gentamicin Induces Laminin 332 and Improves Wound Healing in Junctional Epidermolysis Bullosa Patients with Nonsense Mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : 1021 Intravenous gentamicin therapy for recessive dystrophic epidermolysis bullosa patients harboring nonsense mutations</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : 861 Intravenous gentamicin therapy for junctional epidermolysis bullosa patients harboring nonsense mutations</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35234826" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Molecular and Clinical Outcomes After Intravenous Gentamicin Treatment for Patients With Junctional Epidermolysis Bullosa Caused by Nonsense Variants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35234827" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Evaluation of Systemic Gentamicin as Translational Readthrough Therapy for a Patient With Epidermolysis Bullosa Simplex With Muscular Dystrophy Owing to PLEC1 Pathogenic Nonsense Variants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31132778" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Attenuation of Severe Generalized Junctional Epidermolysis Bullosa by Systemic Treatment with Gentamicin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35234816" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Understanding the Potential Promise and Pitfalls of Intravenous Gentamicin as a Therapy for Epidermolysis Bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18206702" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Cause-specific risks of childhood death in inherited epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22512697" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Long-term follow-up of patients with Herlitz-type junctional epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20566927" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Epidemiology of epidermolysis bullosa in the antipodes: the Australasian Epidermolysis Bullosa Registry with a focus on Herlitz junctional epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19945624" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Kindler syndrome.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
